

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
SUPINE SYSTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Baseline		n	69	71	70	210
		Mean	114.7	114.7	114.6	114.7
		Std. Dev.	9.03	8.92	8.92	8.91
		Median	115.0	115.0	115.0	115.0
		Min	93.0	94.0	95.0	93.0
		Max	134.0	140.0	136.0	140.0
Day 1	3H	n	69	71	70	210
		Mean	-1.1	-1.4	-1.4	-1.3
		Std. Dev.	6.92	6.18	6.15	6.39
		Median	-1.0	-2.0	-1.0	-1.0
		Min	-14.0	-18.0	-16.0	-18.0
		Max	16.0	16.0	11.0	16.0
Day 2	24H	n	69	71	70	210
		Mean	-0.3	-0.6	-1.2	-0.7
		Std. Dev.	7.33	5.96	7.67	7.00
		Median	-1.0	0.0	-0.5	0.0
		Min	-20.0	-11.0	-22.0	-22.0
		Max	13.0	17.0	15.0	17.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
SUPINE SYSTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 3	48H	n	69	71	70	210
		Mean	1.1	0.4	-0.3	0.4
		Std. Dev.	6.41	6.34	6.93	6.56
		Median	1.0	0.0	0.0	0.0
		Min	-19.0	-19.0	-21.0	-21.0
		Max	16.0	16.0	14.0	16.0
Day 4	72H	n	68	71	70	209
		Mean	-0.0	-0.8	0.3	-0.2
		Std. Dev.	6.63	7.37	7.17	7.05
		Median	0.0	-2.0	0.0	0.0
		Min	-14.0	-23.0	-14.0	-23.0
		Max	18.0	16.0	17.0	18.0
Day 5	96H	n	69	71	70	210
		Mean	2.1	1.5	1.3	1.7
		Std. Dev.	7.68	7.69	7.14	7.48
		Median	2.0	1.0	3.5	2.0
		Min	-17.0	-22.0	-20.0	-22.0
		Max	23.0	21.0	15.0	23.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
SUPINE SYSTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 6	120H	n	69	71	70	210
		Mean	1.8	1.2	0.6	1.2
		Std. Dev.	7.53	6.71	8.08	7.44
		Median	1.0	1.0	0.0	1.0
		Min	-17.0	-11.0	-20.0	-20.0
		Max	22.0	23.0	22.0	23.0
Day 7	144H	n	68	71	70	209
		Mean	1.7	2.2	1.8	1.9
		Std. Dev.	7.45	8.30	7.98	7.89
		Median	2.5	1.0	1.0	1.0
		Min	-14.0	-14.0	-12.0	-14.0
		Max	20.0	27.0	19.0	27.0
Day 8	168H	n	69	71	70	210
		Mean	3.0	1.4	3.5	2.6
		Std. Dev.	7.08	6.88	8.12	7.40
		Median	2.0	1.0	4.0	2.0
		Min	-12.0	-12.0	-17.0	-17.0
		Max	23.0	19.0	22.0	23.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
SUPINE SYSTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 9	192H	n	68	71	70	209
		Mean	6.3	6.8	6.2	6.4
		Std. Dev.	7.22	7.00	7.68	7.27
		Median	5.0	6.0	7.0	7.0
		Min	-11.0	-15.0	-15.0	-15.0
		Max	24.0	24.0	19.0	24.0
Day 12	264H	n	68	69	70	207
		Mean	6.8	5.6	4.3	5.6
		Std. Dev.	8.45	7.98	8.13	8.21
		Median	6.0	6.0	5.0	6.0
		Min	-11.0	-17.0	-19.0	-19.0
		Max	30.0	26.0	22.0	30.0
Day 15	336H	n	68	71	69	208
		Mean	5.5	5.8	4.4	5.2
		Std. Dev.	9.30	7.65	7.29	8.10
		Median	5.5	5.0	4.0	5.0
		Min	-18.0	-11.0	-14.0	-18.0
		Max	25.0	37.0	20.0	37.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
SUPINE SYSTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 22	504H	n	67	71	69	207
		Mean	6.5	6.0	4.7	5.8
		Std. Dev.	7.91	7.62	8.96	8.18
		Median	6.0	7.0	6.0	6.0
		Min	-24.0	-11.0	-23.0	-24.0
		Max	25.0	37.0	22.0	37.0
Day 29	672H	n	67	70	70	207
		Mean	6.8	4.4	4.8	5.3
		Std. Dev.	7.04	6.12	8.05	7.16
		Median	7.0	5.0	5.0	5.0
		Min	-12.0	-11.0	-20.0	-20.0
		Max	22.0	17.0	20.0	22.0
Day 36	840H	n	67	69	70	206
		Mean	6.6	5.7	5.4	5.9
		Std. Dev.	7.22	6.69	8.00	7.31
		Median	7.0	5.0	5.0	6.0
		Min	-12.0	-13.0	-15.0	-15.0
		Max	24.0	21.0	22.0	24.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
SUPINE SYSTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 43	1008H	n	67	71	70	208
		Mean	6.1	6.3	5.2	5.8
		Std. Dev.	7.24	7.36	8.71	7.78
		Median	7.0	5.0	7.0	6.5
		Min	-7.0	-7.0	-20.0	-20.0
		Max	22.0	28.0	22.0	28.0
Day 71	1680H	n	69	71	69	209
		Mean	6.0	8.1	4.6	6.3
		Std. Dev.	8.42	6.91	9.89	8.56
		Median	5.0	7.0	5.0	6.0
		Min	-11.0	-4.0	-18.0	-18.0
		Max	26.0	32.0	28.0	32.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
SUPINE DIASTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Baseline		n	69	71	70	210
		Mean	67.7	67.8	67.8	67.8
		Std. Dev.	6.20	5.39	6.16	5.89
		Median	67.0	68.0	67.0	67.0
		Min	51.0	52.0	58.0	51.0
		Max	86.0	83.0	98.0	98.0
Day 1	3H	n	69	71	70	210
		Mean	-0.7	-0.4	-0.7	-0.6
		Std. Dev.	4.73	4.66	3.35	4.27
		Median	0.0	-1.0	0.0	-0.5
		Min	-12.0	-9.0	-10.0	-12.0
		Max	14.0	9.0	8.0	14.0
Day 2	24H	n	69	71	70	210
		Mean	0.2	-0.9	-0.6	-0.4
		Std. Dev.	4.53	3.49	3.52	3.88
		Median	0.0	-1.0	-0.5	-0.5
		Min	-10.0	-8.0	-8.0	-10.0
		Max	13.0	8.0	7.0	13.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
SUPINE DIASTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 3	48H	n	69	71	70	210
		Mean	0.6	-0.1	-0.2	0.1
		Std. Dev.	4.25	4.30	3.78	4.12
		Median	0.0	0.0	0.0	0.0
		Min	-7.0	-12.0	-10.0	-12.0
		Max	13.0	19.0	8.0	19.0
Day 4	72H	n	68	71	70	209
		Mean	0.6	0.1	0.2	0.3
		Std. Dev.	4.46	4.27	4.01	4.23
		Median	0.5	0.0	0.0	0.0
		Min	-12.0	-10.0	-7.0	-12.0
		Max	12.0	11.0	11.0	12.0
Day 5	96H	n	69	71	70	210
		Mean	1.3	0.8	0.9	1.0
		Std. Dev.	5.06	5.17	4.34	4.85
		Median	2.0	0.0	1.0	1.0
		Min	-14.0	-11.0	-10.0	-14.0
		Max	14.0	18.0	12.0	18.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
SUPINE DIASTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 6	120H	n	69	71	70	210
		Mean	0.6	0.5	0.4	0.5
		Std. Dev.	4.39	5.44	5.33	5.05
		Median	1.0	0.0	0.0	0.0
		Min	-15.0	-9.0	-10.0	-15.0
		Max	13.0	24.0	14.0	24.0
Day 7	144H	n	68	71	70	209
		Mean	0.9	1.4	0.7	1.0
		Std. Dev.	5.38	5.75	4.87	5.33
		Median	0.5	1.0	0.5	1.0
		Min	-17.0	-10.0	-14.0	-17.0
		Max	16.0	29.0	13.0	29.0
Day 8	168H	n	69	71	70	210
		Mean	0.7	0.6	1.1	0.8
		Std. Dev.	5.27	4.55	4.87	4.88
		Median	0.0	0.0	1.0	0.0
		Min	-12.0	-7.0	-12.0	-12.0
		Max	15.0	15.0	16.0	16.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
SUPINE DIASTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 9	192H	n	68	71	70	209
		Mean	3.1	4.0	3.5	3.5
		Std. Dev.	5.67	5.58	4.86	5.36
		Median	3.0	4.0	4.0	4.0
		Min	-10.0	-9.0	-8.0	-10.0
		Max	17.0	19.0	14.0	19.0
Day 12	264H	n	68	69	70	207
		Mean	3.5	3.6	2.9	3.3
		Std. Dev.	5.38	5.63	5.12	5.36
		Median	4.0	2.0	3.0	3.0
		Min	-11.0	-9.0	-10.0	-11.0
		Max	21.0	23.0	17.0	23.0
Day 15	336H	n	68	71	69	208
		Mean	3.7	4.3	3.6	3.9
		Std. Dev.	4.76	5.27	4.93	4.98
		Median	4.0	3.0	4.0	4.0
		Min	-6.0	-5.0	-6.0	-6.0
		Max	14.0	21.0	20.0	21.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
SUPINE DIASTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 22	504H	n	67	71	69	207
		Mean	4.0	4.2	3.0	3.7
		Std. Dev.	5.85	4.39	5.63	5.32
		Median	4.0	4.0	2.0	3.0
		Min	-13.0	-4.0	-12.0	-13.0
		Max	19.0	16.0	20.0	20.0
Day 29	672H	n	67	70	70	207
		Mean	4.5	3.4	3.2	3.7
		Std. Dev.	5.47	4.79	4.71	5.00
		Median	5.0	3.0	3.0	4.0
		Min	-11.0	-9.0	-9.0	-11.0
		Max	19.0	15.0	16.0	19.0
Day 36	840H	n	67	69	70	206
		Mean	3.3	3.7	3.0	3.3
		Std. Dev.	5.09	4.93	5.46	5.15
		Median	3.0	3.0	3.0	3.0
		Min	-9.0	-5.0	-14.0	-14.0
		Max	18.0	16.0	19.0	19.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
SUPINE DIASTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 43	1008H	n	67	71	70	208
		Mean	4.4	3.4	3.3	3.7
		Std. Dev.	4.71	5.64	4.89	5.11
		Median	4.0	3.0	3.0	4.0
		Min	-3.0	-12.0	-11.0	-12.0
		Max	18.0	18.0	13.0	18.0
Day 71	1680H	n	69	71	69	209
		Mean	4.0	5.1	3.7	4.3
		Std. Dev.	5.54	5.63	5.67	5.62
		Median	4.0	5.0	4.0	4.0
		Min	-15.0	-7.0	-6.0	-15.0
		Max	21.0	20.0	19.0	21.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
SUPINE PULSE RATE (BPM)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Baseline		n	69	71	70	210
		Mean	57.9	58.5	58.3	58.2
		Std. Dev.	8.98	8.69	7.13	8.27
		Median	57.0	58.0	58.0	58.0
		Min	41.0	34.0	41.0	34.0
		Max	85.0	80.0	79.0	85.0
Day 1	3H	n	69	71	70	210
		Mean	0.5	-0.4	-0.4	-0.1
		Std. Dev.	6.62	5.63	5.56	5.94
		Median	0.0	0.0	0.0	0.0
		Min	-23.0	-17.0	-15.0	-23.0
		Max	21.0	11.0	17.0	21.0
Day 2	24H	n	69	71	70	210
		Mean	-0.1	0.4	0.4	0.2
		Std. Dev.	5.87	7.14	5.68	6.24
		Median	0.0	0.0	0.0	0.0
		Min	-14.0	-21.0	-11.0	-21.0
		Max	10.0	21.0	16.0	21.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
SUPINE PULSE RATE (BPM)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 3	48H	n	69	71	70	210
		Mean	-0.1	1.1	0.7	0.6
		Std. Dev.	6.16	7.33	5.37	6.33
		Median	0.0	2.0	1.5	1.0
		Min	-18.0	-18.0	-13.0	-18.0
		Max	14.0	19.0	15.0	19.0
Day 4	72H	n	68	71	70	209
		Mean	0.2	2.5	0.5	1.1
		Std. Dev.	6.21	7.23	5.93	6.54
		Median	0.0	2.0	0.0	1.0
		Min	-19.0	-15.0	-12.0	-19.0
		Max	13.0	24.0	18.0	24.0
Day 5	96H	n	69	71	70	210
		Mean	1.2	2.1	0.7	1.3
		Std. Dev.	6.87	6.88	5.61	6.47
		Median	2.0	1.0	1.5	1.5
		Min	-21.0	-15.0	-14.0	-21.0
		Max	15.0	19.0	14.0	19.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
SUPINE PULSE RATE (BPM)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 6	120H	n	69	71	70	210
		Mean	2.2	1.8	2.3	2.1
		Std. Dev.	6.42	7.40	6.58	6.79
		Median	2.0	2.0	1.5	2.0
		Min	-18.0	-18.0	-11.0	-18.0
		Max	18.0	27.0	30.0	30.0
Day 7	144H	n	68	71	70	209
		Mean	2.6	3.5	2.5	2.9
		Std. Dev.	7.45	10.50	6.71	8.37
		Median	3.0	3.0	3.0	3.0
		Min	-19.0	-20.0	-12.0	-20.0
		Max	25.0	57.0	19.0	57.0
Day 8	168H	n	69	71	70	210
		Mean	3.1	4.4	3.3	3.6
		Std. Dev.	6.99	10.25	6.90	8.20
		Median	4.0	5.0	4.0	4.0
		Min	-13.0	-13.0	-10.0	-13.0
		Max	23.0	69.0	24.0	69.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
SUPINE PULSE RATE (BPM)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 9	192H	n	68	71	70	209
		Mean	7.3	8.7	8.1	8.0
		Std. Dev.	8.44	10.03	8.25	8.93
		Median	7.0	7.0	7.5	7.0
		Min	-11.0	-15.0	-8.0	-15.0
		Max	31.0	54.0	31.0	54.0
Day 12	264H	n	68	69	70	207
		Mean	8.1	6.4	7.1	7.2
		Std. Dev.	11.32	8.63	8.73	9.61
		Median	6.0	7.0	6.5	6.0
		Min	-16.0	-18.0	-7.0	-18.0
		Max	38.0	33.0	35.0	38.0
Day 15	336H	n	68	71	69	208
		Mean	4.5	4.1	5.6	4.8
		Std. Dev.	9.19	8.96	7.71	8.63
		Median	4.0	4.0	4.0	4.0
		Min	-23.0	-23.0	-9.0	-23.0
		Max	29.0	40.0	25.0	40.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
SUPINE PULSE RATE (BPM)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 22	504H	n	67	71	69	207
		Mean	7.2	6.3	5.6	6.3
		Std. Dev.	9.35	9.23	7.16	8.62
		Median	7.0	5.0	6.0	6.0
		Min	-17.0	-17.0	-9.0	-17.0
		Max	28.0	29.0	36.0	36.0
Day 29	672H	n	67	70	70	207
		Mean	4.9	4.7	5.5	5.0
		Std. Dev.	9.69	7.63	8.97	8.76
		Median	4.0	3.5	4.0	4.0
		Min	-17.0	-15.0	-10.0	-17.0
		Max	37.0	26.0	36.0	37.0
Day 36	840H	n	67	69	70	206
		Mean	7.1	7.2	6.5	7.0
		Std. Dev.	9.26	8.82	9.76	9.25
		Median	6.0	7.0	6.5	6.0
		Min	-13.0	-9.0	-15.0	-15.0
		Max	35.0	31.0	29.0	35.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
SUPINE PULSE RATE (BPM)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 43	1008H	n	67	71	70	208
		Mean	5.2	5.7	6.3	5.8
		Std. Dev.	9.84	9.32	10.71	9.93
		Median	4.0	5.0	4.5	5.0
		Min	-15.0	-15.0	-10.0	-15.0
		Max	29.0	31.0	44.0	44.0
Day 71	1680H	n	69	71	69	209
		Mean	4.8	6.2	4.9	5.3
		Std. Dev.	7.55	9.99	10.14	9.29
		Median	3.0	5.0	3.0	4.0
		Min	-10.0	-12.0	-17.0	-17.0
		Max	24.0	43.0	35.0	43.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
SPO2 PULSE OXIMETRY % (%)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Baseline		n	68	71	68	207
		Mean	98.3	98.1	98.1	98.2
		Std. Dev.	1.38	1.34	1.34	1.35
		Median	98.0	98.0	98.0	98.0
		Min	95.0	96.0	95.0	95.0
		Max	100.0	100.0	100.0	100.0
Day 1	3H	n	68	71	68	207
		Mean	0.1	0.0	0.1	0.1
		Std. Dev.	1.34	1.34	1.25	1.30
		Median	0.0	0.0	0.0	0.0
		Min	-3.0	-3.0	-3.0	-3.0
		Max	3.0	4.0	3.0	4.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
TEMPERATURE (C)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Baseline		n	69	71	70	210
		Mean	36.2	36.1	36.1	36.1
		Std. Dev.	0.33	0.32	0.34	0.33
		Median	36.2	36.2	36.2	36.2
		Min	35.3	35.2	35.4	35.2
		Max	37.0	36.7	36.8	37.0
Day 1	3H	n	69	71	70	210
		Mean	0.2	0.1	0.1	0.1
		Std. Dev.	0.39	0.38	0.35	0.37
		Median	0.2	0.1	0.1	0.1
		Min	-0.9	-1.2	-0.6	-1.2
		Max	1.1	0.8	1.2	1.2
Day 2	24H	n	69	71	70	210
		Mean	0.0	0.0	0.1	0.1
		Std. Dev.	0.35	0.35	0.37	0.36
		Median	0.0	0.0	0.1	0.0
		Min	-1.1	-0.6	-0.6	-1.1
		Max	0.8	1.0	1.1	1.1

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
TEMPERATURE (C)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 3	48H	n	69	71	70	210
		Mean	0.0	0.1	0.0	0.0
		Std. Dev.	0.43	0.38	0.40	0.40
		Median	0.0	0.1	0.1	0.1
		Min	-1.1	-1.2	-1.1	-1.2
		Max	0.8	1.0	0.8	1.0
Day 4	72H	n	69	71	70	210
		Mean	-0.0	0.0	0.0	0.0
		Std. Dev.	0.45	0.44	0.44	0.44
		Median	0.1	0.1	0.0	0.0
		Min	-1.0	-1.2	-0.9	-1.2
		Max	1.1	1.1	1.2	1.2
Day 5	96H	n	69	71	70	210
		Mean	0.1	-0.0	0.1	0.1
		Std. Dev.	0.37	0.37	0.43	0.39
		Median	0.0	0.0	0.1	0.1
		Min	-1.0	-0.9	-0.7	-1.0
		Max	1.0	1.0	1.2	1.2

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
TEMPERATURE (C)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 6	120H	n	69	71	70	210
		Mean	0.1	-0.0	0.1	0.0
		Std. Dev.	0.42	0.35	0.41	0.39
		Median	0.0	0.0	0.0	0.0
		Min	-1.0	-1.0	-0.9	-1.0
		Max	1.0	0.8	0.9	1.0
Day 7	144H	n	67	71	70	208
		Mean	0.1	0.0	0.1	0.1
		Std. Dev.	0.38	0.42	0.42	0.41
		Median	0.1	0.0	0.1	0.1
		Min	-0.7	-0.9	-1.0	-1.0
		Max	0.9	0.9	1.0	1.0
Day 8	168H	n	69	71	70	210
		Mean	0.2	0.2	0.2	0.2
		Std. Dev.	0.38	0.38	0.38	0.38
		Median	0.2	0.2	0.2	0.2
		Min	-0.6	-0.6	-0.5	-0.6
		Max	1.3	1.3	1.1	1.3

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
TEMPERATURE (C)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 9	192H	n	68	71	70	209
		Mean	0.1	0.2	0.2	0.2
		Std. Dev.	0.43	0.40	0.42	0.42
		Median	0.1	0.1	0.3	0.2
		Min	-0.8	-1.0	-0.9	-1.0
		Max	1.5	1.1	1.1	1.5
Day 12	264H	n	68	69	70	207
		Mean	0.0	0.1	0.0	0.0
		Std. Dev.	0.47	0.46	0.44	0.45
		Median	0.0	0.0	0.1	0.0
		Min	-1.1	-1.1	-1.0	-1.1
		Max	1.3	1.3	1.2	1.3
Day 15	336H	n	68	71	69	208
		Mean	-0.0	-0.0	0.0	-0.0
		Std. Dev.	0.48	0.43	0.43	0.45
		Median	0.1	0.0	0.0	0.0
		Min	-1.0	-1.2	-0.8	-1.2
		Max	1.0	0.8	1.2	1.2

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
TEMPERATURE (C)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 22	504H	n	67	71	69	207
		Mean	0.1	0.0	0.0	0.0
		Std. Dev.	0.49	0.45	0.43	0.46
		Median	0.1	0.0	0.0	0.0
		Min	-1.1	-1.1	-1.0	-1.1
		Max	1.2	1.2	0.9	1.2
Day 29	672H	n	67	70	70	207
		Mean	0.0	-0.0	-0.0	-0.0
		Std. Dev.	0.46	0.47	0.47	0.46
		Median	0.0	-0.1	0.0	0.0
		Min	-1.0	-1.1	-1.1	-1.1
		Max	1.3	1.3	1.2	1.3
Day 36	840H	n	67	69	70	206
		Mean	0.0	-0.0	0.1	0.0
		Std. Dev.	0.49	0.44	0.48	0.47
		Median	0.0	0.0	0.1	0.0
		Min	-1.2	-1.2	-1.2	-1.2
		Max	1.2	1.1	1.0	1.2

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
TEMPERATURE (C)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 43	1008H	n	67	71	70	208
		Mean	-0.0	-0.1	0.0	-0.0
		Std. Dev.	0.50	0.44	0.43	0.45
		Median	0.0	0.0	0.1	0.0
		Min	-1.2	-0.9	-0.9	-1.2
		Max	1.2	1.2	1.0	1.2
Day 71	1680H	n	69	71	69	209
		Mean	0.1	0.1	0.1	0.1
		Std. Dev.	0.46	0.42	0.44	0.44
		Median	0.2	0.1	0.1	0.1
		Min	-1.0	-0.9	-0.9	-1.0
		Max	1.0	0.9	1.1	1.1

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
RESPIRATORY RATE (BREATHS/MIN)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Baseline		n	69	71	70	210
		Mean	14.6	14.6	14.9	14.7
		Std. Dev.	2.56	2.59	2.78	2.63
		Median	14.0	14.0	16.0	14.5
		Min	10.0	8.0	8.0	8.0
		Max	20.0	20.0	20.0	20.0
Day 1	3H	n	69	71	70	210
		Mean	0.0	-0.5	0.3	-0.0
		Std. Dev.	3.05	3.19	2.81	3.03
		Median	0.0	0.0	0.0	0.0
		Min	-8.0	-10.0	-6.0	-10.0
		Max	8.0	8.0	8.0	8.0
Day 2	24H	n	69	71	70	210
		Mean	0.3	0.5	0.3	0.4
		Std. Dev.	3.05	3.03	3.77	3.29
		Median	0.0	0.0	0.0	0.0
		Min	-8.0	-6.0	-6.0	-8.0
		Max	6.0	8.0	10.0	10.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
RESPIRATORY RATE (BREATHS/MIN)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 3	48H	n	69	71	70	210
		Mean	0.1	0.4	0.1	0.2
		Std. Dev.	3.26	3.31	3.22	3.25
		Median	0.0	0.0	0.0	0.0
		Min	-8.0	-8.0	-8.0	-8.0
		Max	10.0	8.0	8.0	10.0
Day 4	72H	n	69	71	70	210
		Mean	0.3	0.3	-0.3	0.1
		Std. Dev.	3.38	3.01	3.43	3.27
		Median	0.0	0.0	0.0	0.0
		Min	-8.0	-6.0	-8.0	-8.0
		Max	14.0	6.0	8.0	14.0
Day 5	96H	n	69	71	70	210
		Mean	0.1	0.3	0.3	0.2
		Std. Dev.	2.90	3.29	3.88	3.37
		Median	0.0	0.0	0.0	0.0
		Min	-6.0	-8.0	-10.0	-10.0
		Max	8.0	6.0	14.0	14.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
RESPIRATORY RATE (BREATHS/MIN)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 6	120H	n	69	70	70	209
		Mean	0.1	0.9	0.2	0.4
		Std. Dev.	3.27	3.14	3.22	3.21
		Median	0.0	0.0	0.0	0.0
		Min	-8.0	-6.0	-8.0	-8.0
		Max	8.0	8.0	6.0	8.0
Day 7	144H	n	66	71	70	207
		Mean	0.1	-0.0	0.1	0.1
		Std. Dev.	3.09	3.49	3.51	3.36
		Median	0.0	0.0	0.0	0.0
		Min	-8.0	-8.0	-8.0	-8.0
		Max	6.0	8.0	8.0	8.0
Day 8	168H	n	68	70	69	207
		Mean	0.4	0.1	-0.1	0.1
		Std. Dev.	3.15	3.39	2.92	3.16
		Median	0.0	0.0	0.0	0.0
		Min	-8.0	-6.0	-6.0	-8.0
		Max	10.0	8.0	6.0	10.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
RESPIRATORY RATE (BREATHS/MIN)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 9	192H	n	68	71	70	209
		Mean	0.9	1.2	0.5	0.8
		Std. Dev.	3.44	3.54	3.46	3.48
		Median	0.0	0.0	0.0	0.0
		Min	-6.0	-6.0	-7.0	-7.0
		Max	10.0	10.0	8.0	10.0
Day 12	264H	n	68	69	70	207
		Mean	1.1	1.4	0.7	1.0
		Std. Dev.	3.43	3.11	3.69	3.42
		Median	2.0	2.0	0.0	2.0
		Min	-8.0	-6.0	-10.0	-10.0
		Max	8.0	8.0	8.0	8.0
Day 15	336H	n	68	71	69	208
		Mean	1.5	0.6	0.4	0.8
		Std. Dev.	3.36	3.13	3.41	3.32
		Median	2.0	0.0	0.0	0.0
		Min	-6.0	-6.0	-6.0	-6.0
		Max	10.0	10.0	8.0	10.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
RESPIRATORY RATE (BREATHS/MIN)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 22	504H	n	67	71	69	207
		Mean	1.6	1.5	1.1	1.4
		Std. Dev.	3.30	2.97	3.74	3.34
		Median	2.0	2.0	0.0	2.0
		Min	-8.0	-6.0	-6.0	-8.0
		Max	8.0	8.0	8.0	8.0
Day 29	672H	n	66	70	69	205
		Mean	1.2	1.1	0.7	1.0
		Std. Dev.	3.49	3.21	3.85	3.51
		Median	2.0	1.0	0.0	0.0
		Min	-6.0	-8.0	-8.0	-8.0
		Max	8.0	10.0	10.0	10.0
Day 36	840H	n	67	69	70	206
		Mean	0.8	1.1	0.7	0.9
		Std. Dev.	2.79	3.35	3.49	3.22
		Median	0.0	2.0	0.0	1.0
		Min	-6.0	-8.0	-8.0	-8.0
		Max	10.0	8.0	8.0	10.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Vital Signs Data - Safety Analysis Set
RESPIRATORY RATE (BREATHS/MIN)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Analysis Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 43	1008H	n	67	71	70	208
		Mean	0.6	0.4	0.5	0.5
		Std. Dev.	3.41	3.43	3.25	3.35
		Median	0.0	0.0	0.0	0.0
		Min	-8.0	-8.0	-8.0	-8.0
		Max	8.0	8.0	8.0	8.0
Day 71	1680H	n	68	71	69	208
		Mean	0.9	0.6	0.6	0.7
		Std. Dev.	3.95	3.47	3.55	3.64
		Median	0.0	0.0	0.0	0.0
		Min	-8.0	-6.0	-6.0	-8.0
		Max	12.0	8.0	10.0	12.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:16)

090177e18ebdbab4\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.2.1
PF-06410293 Protocol B5381001
Categorical Summary of Vital Signs Data - Absolute Values - Safety Analysis Set

Parameter (units)	Criteria	Adalimumab-Pfizer		Adalimumab-US		Adalimumab-EU		Total	
		N	n (%)	N	n (%)	N	n (%)	N	n (%)
SUPINE SYSTOLIC BLOOD PRESSURE (MMHG)	Value <90 mmHg	69	2 (2.9)	71	1 (1.4)	70	0	210	3 (1.4)
SUPINE DIASTOLIC BLOOD PRESSURE (MMHG)	Value <50 mmHg	69	1 (1.4)	71	1 (1.4)	70	0	210	2 (1.0)
SUPINE PULSE RATE (BPM)	Value <40 bpm	69	0	71	3 (4.2)	70	1 (1.4)	210	4 (1.9)
	Value >120 bpm	69	0	71	1 (1.4)	70	0	210	1 (0.5)

N=number of subjects evaluated against criteria. n=number of subjects that met criteria.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.2 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 16MAY2018 (04:57)

Table 14.3.4.2.2.2
PF-06410293 Protocol B5381001
Categorical Summary of Vital Signs Data - Maximum Increase from Baseline - Safety Analysis Set

Parameter (units)	Criteria	Adalimumab-Pfizer		Adalimumab-US		Adalimumab-EU		Total	
		N	n (%)	N	n (%)	N	n (%)	N	n (%)
SUPINE SYSTOLIC BLOOD PRESSURE (MMHG)	Max increase from baseline \geq 30 mmHg	69	1 (1.4)	71	1 (1.4)	70	0	210	2 (1.0)
SUPINE DIASTOLIC BLOOD PRESSURE (MMHG)	Max increase from baseline \geq 20 mmHg	69	2 (2.9)	71	4 (5.6)	70	1 (1.4)	210	7 (3.3)

Baseline is defined as the most recent measurement prior to dosing.

N=number of subjects evaluated against criteria. n=number of subjects that met criteria.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.2 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 16MAY2018 (04:59)

Table 14.3.4.2.2.3
PF-06410293 Protocol B5381001
Categorical Summary of Vital Signs Data - Maximum Decrease from Baseline - Safety Analysis Set

Parameter (units)	Criteria	Adalimumab-Pfizer		Adalimumab-US		Adalimumab-EU		Total	
		N	n (%)	N	n (%)	N	n (%)	N	n (%)
SUPINE SYSTOLIC BLOOD PRESSURE (MMHG)	Max decrease from baseline \geq 30 mmHg	69	0	71	0	70	0	210	0
SUPINE DIASTOLIC BLOOD PRESSURE (MMHG)	Max decrease from baseline \geq 20 mmHg	69	0	71	0	70	0	210	0

Baseline is defined as the most recent measurement prior to dosing.

N=number of subjects evaluated against criteria. n=number of subjects that met criteria.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.2 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 16MAY2018 (05:03)

Table 14.3.4.3.1.1
PF-06410293 Protocol B5381001
ECG Data Absolute Values - Safety Analysis Set
RR INTERVAL (msec)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Planned Timepoint	Time Post Dose	Summary Statistics				
SCREENING		n	69	71	70	210
		Mean	1074.7	1045.0	1074.2	1064.5
		Std. Dev.	156.92	165.19	154.95	158.98
		Median	1071.0	1017.0	1081.0	1053.0
		Min	732.0	779.0	741.0	732.0
		Max	1463.0	1463.0	1538.0	1538.0
Day 1	0H	n	69	71	70	210
		Mean	1061.1	1065.0	1050.0	1058.7
		Std. Dev.	158.92	162.14	139.93	153.39
		Median	1034.0	1034.0	1034.0	1034.0
		Min	723.0	732.0	732.0	723.0
		Max	1463.0	1622.0	1429.0	1622.0
Day 8	168H	n	69	71	70	210
		Mean	992.5	967.5	988.8	982.8
		Std. Dev.	136.88	160.28	139.87	145.88
		Median	984.0	968.0	960.0	968.0
		Min	759.0	469.0	698.0	469.0
		Max	1364.0	1463.0	1463.0	1463.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.3.1 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 14JUN2018 (22:56)

Table 14.3.4.3.1.1
PF-06410293 Protocol B5381001
ECG Data Absolute Values - Safety Analysis Set
RR INTERVAL (msec)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Planned Timepoint	Time Post Dose	Summary Statistics				
Day 71	1680H	n	69	71	69	209
		Mean	989.9	967.1	972.8	976.5
		Std. Dev.	162.26	167.59	152.69	160.55
		Median	984.0	938.0	984.0	968.0
		Min	682.0	645.0	659.0	645.0
		Max	1395.0	1500.0	1538.0	1538.0

090177e18ebdbabe\Final\Final On: 15-Jun-2018 05:27 (GMT)

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.3.1 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 14JUN2018 (22:56)

Table 14.3.4.3.1.1
PF-06410293 Protocol B5381001
ECG Data Absolute Values - Safety Analysis Set
HEART RATE (bpm)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Planned Timepoint	Time Post Dose	Summary Statistics				
SCREENING		n	69	71	70	210
		Mean	57.0	58.7	57.0	57.6
		Std. Dev.	8.43	8.58	8.37	8.46
		Median	56.0	59.0	55.5	57.0
		Min	41.0	41.0	39.0	39.0
		Max	82.0	77.0	81.0	82.0
Day 1	0H	n	69	71	70	210
		Mean	57.8	57.5	58.1	57.8
		Std. Dev.	8.47	8.25	7.61	8.08
		Median	58.0	58.0	58.0	58.0
		Min	41.0	37.0	42.0	37.0
		Max	83.0	82.0	82.0	83.0
Day 8	168H	n	69	71	70	210
		Mean	61.5	63.8	61.8	62.4
		Std. Dev.	7.85	11.99	8.55	9.67
		Median	61.0	62.0	62.5	62.0
		Min	44.0	41.0	41.0	41.0
		Max	79.0	128.0	86.0	128.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.3.1 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 14JUN2018 (22:56)

Table 14.3.4.3.1.1
PF-06410293 Protocol B5381001
ECG Data Absolute Values - Safety Analysis Set
HEART RATE (bpm)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Planned Timepoint	Time Post Dose	Summary Statistics				
Day 71	1680H	n	69	71	69	209
		Mean	62.3	63.8	63.2	63.1
		Std. Dev.	10.43	10.53	9.94	10.27
		Median	61.0	64.0	61.0	62.0
		Min	43.0	40.0	39.0	39.0
		Max	88.0	93.0	91.0	93.0

090177e18ebdbabe\Final\Final On: 15-Jun-2018 05:27 (GMT)

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.3.1 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 14JUN2018 (22:56)

Table 14.3.4.3.1.1
PF-06410293 Protocol B5381001
ECG Data Absolute Values - Safety Analysis Set
PR INTERVAL (msec)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Planned Timepoint	Time Post Dose	Summary Statistics				
SCREENING		n	69	71	70	210
		Mean	167.1	164.6	162.9	164.8
		Std. Dev.	21.06	22.08	21.78	21.61
		Median	168.0	160.0	156.0	162.0
		Min	112.0	124.0	116.0	112.0
		Max	216.0	220.0	212.0	220.0
Day 1	0H	n	69	71	70	210
		Mean	169.4	167.3	167.8	168.2
		Std. Dev.	20.68	21.62	21.39	21.16
		Median	168.0	164.0	164.0	168.0
		Min	116.0	120.0	116.0	116.0
		Max	216.0	220.0	228.0	228.0
Day 8	168H	n	69	71	70	210
		Mean	169.4	167.3	166.5	167.7
		Std. Dev.	20.49	20.71	21.11	20.71
		Median	168.0	168.0	164.0	168.0
		Min	120.0	128.0	112.0	112.0
		Max	220.0	212.0	224.0	224.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.3.1 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 14JUN2018 (22:56)

Table 14.3.4.3.1.1
PF-06410293 Protocol B5381001
ECG Data Absolute Values - Safety Analysis Set
PR INTERVAL (msec)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Planned Timepoint	Time Post Dose	Summary Statistics				
Day 71	1680H	n	69	71	69	209
		Mean	166.4	162.3	163.1	163.9
		Std. Dev.	17.92	20.52	21.95	20.18
		Median	168.0	160.0	164.0	164.0
		Min	120.0	124.0	112.0	112.0
		Max	208.0	216.0	216.0	216.0

090177e18ebdbabe\Final\Final On: 15-Jun-2018 05:27 (GMT)

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.3.1 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 14JUN2018 (22:56)

Table 14.3.4.3.1.1
PF-06410293 Protocol B5381001
ECG Data Absolute Values - Safety Analysis Set
QRS COMPLEX (msec)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Planned Timepoint	Time Post Dose	Summary Statistics				
SCREENING		n	69	71	70	210
		Mean	93.9	93.5	92.6	93.3
		Std. Dev.	8.17	8.30	9.17	8.54
		Median	94.0	94.0	93.0	94.0
		Min	74.0	76.0	72.0	72.0
		Max	112.0	114.0	108.0	114.0
Day 1	0H	n	69	71	70	210
		Mean	93.4	93.9	92.2	93.2
		Std. Dev.	7.97	8.04	9.07	8.36
		Median	92.0	94.0	94.0	94.0
		Min	74.0	76.0	68.0	68.0
		Max	114.0	112.0	106.0	114.0
Day 8	168H	n	69	71	70	210
		Mean	93.6	92.3	91.5	92.5
		Std. Dev.	7.65	8.53	9.12	8.47
		Median	94.0	92.0	92.0	92.0
		Min	80.0	72.0	72.0	72.0
		Max	116.0	112.0	110.0	116.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.3.1 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 14JUN2018 (22:56)

Table 14.3.4.3.1.1
PF-06410293 Protocol B5381001
ECG Data Absolute Values - Safety Analysis Set
QRS COMPLEX (msec)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Planned Timepoint	Time Post Dose	Summary Statistics				
Day 71	1680H	n	69	71	69	209
		Mean	93.5	92.8	91.4	92.6
		Std. Dev.	7.96	8.52	9.12	8.55
		Median	92.0	94.0	94.0	94.0
		Min	78.0	72.0	70.0	70.0
		Max	114.0	114.0	110.0	114.0

090177e18ebdbabe\Final\Final On: 15-Jun-2018 05:27 (GMT)

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.3.1 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 14JUN2018 (22:56)

Table 14.3.4.3.1.1
PF-06410293 Protocol B5381001
ECG Data Absolute Values - Safety Analysis Set
QT INTERVAL (msec)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Planned Timepoint	Time Post Dose	Summary Statistics				
SCREENING		n	69	71	70	210
		Mean	420.5	416.9	416.9	418.1
		Std. Dev.	27.31	29.09	27.90	28.03
		Median	420.0	412.0	416.0	416.0
		Min	356.0	352.0	352.0	352.0
		Max	496.0	492.0	484.0	496.0
Day 1	0H	n	69	71	70	210
		Mean	415.6	416.2	413.1	415.0
		Std. Dev.	26.45	27.21	25.48	26.30
		Median	412.0	412.0	408.0	412.0
		Min	352.0	368.0	348.0	348.0
		Max	488.0	508.0	496.0	508.0
Day 8	168H	n	69	71	70	210
		Mean	399.1	397.4	397.0	397.8
		Std. Dev.	23.75	29.89	25.37	26.38
		Median	396.0	396.0	396.0	396.0
		Min	348.0	296.0	348.0	296.0
		Max	468.0	484.0	480.0	484.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.3.1 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 14JUN2018 (22:56)

Table 14.3.4.3.1.1
PF-06410293 Protocol B5381001
ECG Data Absolute Values - Safety Analysis Set
QT INTERVAL (msec)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Planned Timepoint	Time Post Dose	Summary Statistics				
Day 71	1680H	n	69	71	69	209
		Mean	405.7	402.4	402.1	403.4
		Std. Dev.	28.40	28.86	28.98	28.66
		Median	408.0	400.0	404.0	404.0
		Min	352.0	332.0	348.0	332.0
		Max	472.0	500.0	508.0	508.0

090177e18ebdbabe\Final\Final On: 15-Jun-2018 05:27 (GMT)

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.3.1 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 14JUN2018 (22:56)

Table 14.3.4.3.1.1
PF-06410293 Protocol B5381001
ECG Data Absolute Values - Safety Analysis Set
QTCF INTERVAL (FRIDERICIA'S CORRECTION) (msec)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Planned Timepoint	Time Post Dose	Summary Statistics				
SCREENING		n	69	71	70	210
		Mean	411.5	411.8	407.9	410.4
		Std. Dev.	15.33	15.89	16.89	16.08
		Median	414.0	413.0	409.5	411.0
		Min	377.0	374.0	359.0	359.0
		Max	449.0	441.0	442.0	449.0
Day 1	0H	n	69	71	70	210
		Mean	408.4	408.5	407.2	408.0
		Std. Dev.	14.99	15.85	16.31	15.66
		Median	408.0	407.0	407.0	407.0
		Min	350.0	380.0	378.0	350.0
		Max	450.0	444.0	443.0	450.0
Day 8	168H	n	69	71	70	210
		Mean	400.8	402.8	399.4	401.0
		Std. Dev.	14.58	16.94	16.91	16.17
		Median	402.0	400.0	404.0	402.0
		Min	364.0	366.0	359.0	359.0
		Max	431.0	448.0	431.0	448.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.3.1 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 14JUN2018 (22:56)

090177e18ebdbabe\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.3.1.1
PF-06410293 Protocol B5381001
ECG Data Absolute Values - Safety Analysis Set
QTCF INTERVAL (FRIDERICIA'S CORRECTION) (msec)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Planned Timepoint	Time Post Dose	Summary Statistics				
Day 71	1680H	n	69	71	69	209
		Mean	408.2	408.0	406.7	407.6
		Std. Dev.	15.16	14.03	16.30	15.12
		Median	408.0	407.0	407.0	408.0
		Min	382.0	382.0	356.0	356.0
		Max	453.0	444.0	444.0	453.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.3.1 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 14JUN2018 (22:56)

Table 14.3.4.3.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for ECG Data - Safety Analysis Set
RR INTERVAL (msec)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Time Post Dose	Summary Statistics				
Baseline	0H	n	69	71	70	210
		Mean	1061.1	1065.0	1050.0	1058.7
		Std. Dev.	158.92	162.14	139.93	153.39
		Median	1034.0	1034.0	1034.0	1034.0
		Min	723.0	732.0	732.0	723.0
		Max	1463.0	1622.0	1429.0	1622.0
Day 8	168H	n	69	71	70	210
		Mean	-68.6	-97.5	-61.2	-75.9
		Std. Dev.	107.25	108.44	114.57	110.74
		Median	-65.0	-91.0	-61.0	-67.5
		Min	-316.0	-515.0	-395.0	-515.0
		Max	122.0	206.0	222.0	222.0
Day 71	1680H	n	69	71	69	209
		Mean	-71.3	-97.9	-78.2	-82.6
		Std. Dev.	127.65	139.07	149.50	138.82
		Median	-58.0	-96.0	-70.0	-75.0
		Min	-367.0	-550.0	-432.0	-550.0
		Max	194.0	250.0	248.0	250.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.3.4 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 14JUN2018 (22:39)

Table 14.3.4.3.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for ECG Data - Safety Analysis Set
HEART RATE (bpm)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Time Post Dose	Summary Statistics				
Baseline	0H	n	69	71	70	210
		Mean	57.8	57.5	58.1	57.8
		Std. Dev.	8.47	8.25	7.61	8.08
		Median	58.0	58.0	58.0	58.0
		Min	41.0	37.0	42.0	37.0
		Max	83.0	82.0	82.0	83.0
Day 8	168H	n	69	71	70	210
		Mean	3.7	6.3	3.7	4.6
		Std. Dev.	6.37	9.63	6.95	7.86
		Median	4.0	4.0	3.5	4.0
		Min	-12.0	-18.0	-16.0	-18.0
		Max	17.0	67.0	22.0	67.0
Day 71	1680H	n	69	71	69	209
		Mean	4.5	6.2	5.1	5.3
		Std. Dev.	8.09	9.22	9.79	9.05
		Median	4.0	6.0	4.0	4.0
		Min	-12.0	-12.0	-14.0	-14.0
		Max	27.0	40.0	36.0	40.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.3.4 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 14JUN2018 (22:39)

090177e18ebdb7f3\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.3.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for ECG Data - Safety Analysis Set
PR INTERVAL (msec)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Time Post Dose	Summary Statistics				
Baseline	0H	n	69	71	70	210
		Mean	169.4	167.3	167.8	168.2
		Std. Dev.	20.68	21.62	21.39	21.16
		Median	168.0	164.0	164.0	168.0
		Min	116.0	120.0	116.0	116.0
		Max	216.0	220.0	228.0	228.0
Day 8	168H	n	69	71	70	210
		Mean	0.0	0.0	-1.3	-0.4
		Std. Dev.	10.52	8.73	8.47	9.25
		Median	0.0	0.0	-2.0	0.0
		Min	-24.0	-29.0	-20.0	-29.0
		Max	52.0	28.0	32.0	52.0
Day 71	1680H	n	69	71	69	209
		Mean	-3.1	-5.0	-4.4	-4.2
		Std. Dev.	10.77	11.31	10.43	10.82
		Median	-4.0	-4.0	-4.0	-4.0
		Min	-28.0	-40.0	-32.0	-40.0
		Max	32.0	22.0	20.0	32.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.3.4 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 14JUN2018 (22:39)

090177e18ebdb7f3\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.3.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for ECG Data - Safety Analysis Set
QRS COMPLEX (msec)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Time Post Dose	Summary Statistics				
Baseline	0H	n	69	71	70	210
		Mean	93.4	93.9	92.2	93.2
		Std. Dev.	7.97	8.04	9.07	8.36
		Median	92.0	94.0	94.0	94.0
		Min	74.0	76.0	68.0	68.0
		Max	114.0	112.0	106.0	114.0
Day 8	168H	n	69	71	70	210
		Mean	0.2	-1.6	-0.8	-0.7
		Std. Dev.	4.61	4.66	4.57	4.65
		Median	0.0	-2.0	0.0	0.0
		Min	-14.0	-16.0	-20.0	-20.0
		Max	10.0	12.0	10.0	12.0
Day 71	1680H	n	69	71	69	209
		Mean	0.1	-1.1	-0.7	-0.5
		Std. Dev.	5.57	5.36	5.61	5.51
		Median	0.0	0.0	0.0	0.0
		Min	-18.0	-20.0	-22.0	-22.0
		Max	12.0	18.0	14.0	18.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.3.4 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 14JUN2018 (22:39)

090177e18ebdb7f3\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.3.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for ECG Data - Safety Analysis Set
QT INTERVAL (msec)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Time Post Dose	Summary Statistics				
Baseline	0H	n	69	71	70	210
		Mean	415.6	416.2	413.1	415.0
		Std. Dev.	26.45	27.21	25.48	26.30
		Median	412.0	412.0	408.0	412.0
		Min	352.0	368.0	348.0	348.0
		Max	488.0	508.0	496.0	508.0
Day 8	168H	n	69	71	70	210
		Mean	-16.5	-18.8	-16.1	-17.2
		Std. Dev.	15.23	17.19	16.30	16.24
		Median	-16.0	-20.0	-16.0	-16.0
		Min	-64.0	-88.0	-60.0	-88.0
		Max	8.0	28.0	28.0	28.0
Day 71	1680H	n	69	71	69	209
		Mean	-9.9	-13.7	-11.2	-11.6
		Std. Dev.	20.78	22.57	21.81	21.70
		Median	-8.0	-16.0	-12.0	-12.0
		Min	-64.0	-92.0	-60.0	-92.0
		Max	32.0	32.0	36.0	36.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.3.4 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 14JUN2018 (22:39)

090177e18ebdb7f3\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.3.1.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for ECG Data - Safety Analysis Set
QTCF INTERVAL (FRIDERICIA'S CORRECTION) (msec)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Time Post Dose	Summary Statistics				
Baseline	0H	n	69	71	70	210
		Mean	408.4	408.5	407.2	408.0
		Std. Dev.	14.99	15.85	16.31	15.66
		Median	408.0	407.0	407.0	407.0
		Min	350.0	380.0	378.0	350.0
		Max	450.0	444.0	443.0	450.0
Day 8	168H	n	69	71	70	210
		Mean	-7.6	-5.7	-7.8	-7.0
		Std. Dev.	10.84	11.00	11.01	10.94
		Median	-8.0	-6.0	-7.0	-7.0
		Min	-47.0	-26.0	-37.0	-47.0
		Max	22.0	27.0	12.0	27.0
Day 71	1680H	n	69	71	69	209
		Mean	-0.2	-0.5	-0.6	-0.4
		Std. Dev.	12.50	11.54	12.95	12.28
		Median	1.0	-1.0	1.0	0.0
		Min	-28.0	-22.0	-32.0	-32.0
		Max	32.0	34.0	29.0	34.0

Baseline is defined as the most recent measurement prior to dosing.

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.3.4 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 14JUN2018 (22:39)

090177e18ebdb7f3\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.3.2.1
PF-06410293 Protocol B5381001
Categorical Summary of ECG Data - Absolute Values - Safety Analysis Set

Parameter (units)	Criteria	Adalimumab-Pfizer		Adalimumab-US		Adalimumab-EU		Total	
		N	n (%)	N	n (%)	N	n (%)	N	n (%)
PR INTERVAL (msec)	Maximum Value ≥300	69	0	71	0	70	0	210	0
QRS COMPLEX (msec)	Maximum Value ≥140	69	0	71	0	70	0	210	0
QT INTERVAL (msec)	Maximum Value ≥500	69	0	71	1 (1.4)	70	1 (1.4)	210	2 (1.0)
QTCF INTERVAL (FRIDERICIA'S CORRECTION) (msec)	450≤ Maximum Value <480	69	1 (1.4)	71	0	70	0	210	1 (0.5)
	480≤ Maximum Value <500	69	0	71	0	70	0	210	0
	Maximum Value ≥500	69	0	71	0	70	0	210	0

N=number of subjects evaluated against criteria. n=number of subjects that met criteria.

The number (%) of subjects with maximum post dose ECG data are tabulated by treatment.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.3.3 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 14JUN2018 (22:40)

Table 14.3.4.3.2.2
PF-06410293 Protocol B5381001
Categorical Summary of ECG Data - Maximum Increase from Baseline - Safety Analysis Set

Parameter (units)	Criteria	Adalimumab-Pfizer		Adalimumab-US		Adalimumab-EU		Total	
		N	n (%)	N	n (%)	N	n (%)	N	n (%)
PR INTERVAL (msec)	Max Percentage Increase from Baseline \geq 25/50%	69	0	71	0	70	0	210	0
QRS COMPLEX (msec)	Max Percentage Increase from Baseline \geq 50%	69	0	71	0	70	0	210	0
QTCF INTERVAL (FRIDERICIA'S CORRECTION) (msec)	$30 \leq$ Max Increase from Baseline <60	69	1 (1.4)	71	1 (1.4)	70	0	210	2 (1.0)
	Max Increase from Baseline \geq 60	69	0	71	0	70	0	210	0

Baseline is defined as the most recent measurement prior to dosing.

N=number of subjects evaluated against criteria. n=number of subjects that met criteria.

Max Percentage Increase from Baseline \geq 25/50% means max percentage increase from baseline \geq 25% when baseline >200 msec or max percentage increase from baseline \geq 50% when baseline \leq 200 msec.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.3.3 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 14JUN2018 (22:41)

Table 14.4.2.1.1
PF-06410293 Protocol B5381001
Serum Drug Concentration (ng/mL) versus Time Summary (Day 1-43) - PP Analysis Set
Treatment Group=Adalimumab-Pfizer

Planned Time Post Dose	N	NALQ	Mean	SD	CV(%)	Median	Min	Max
0 H	66	0						
3 H	66	23	179.4	330.11	184	0.0000	0.000	2080
12 H	66	65	1262	773.61	61	1185	0.000	4940
24 H	66	65	1743	875.87	50	1690	0.000	5320
48 H	66	66	2573	1123.7	44	2450	508	6310
72 H	66	66	3020	1215.8	40	2920	742	6640
96 H	66	66	3228	1199.4	37	3115	856	7060
120 H	66	66	3335	1172.5	35	3305	951	6610
144 H	66	66	3381	1147.3	34	3335	1000	6490
168 H	66	66	3414	1098.1	32	3275	1240	6200
192 H	66	66	3400	1051.3	31	3305	1130	6010
264 H	66	66	3128	847.46	27	3175	1090	5310
336 H	66	66	2972	798.05	27	2985	1130	5230
504 H	65	65	2291	726.10	32	2260	644	3920
672 H	66	66	1755	654.29	37	1750	387	3300
840 H	66	64	1294	651.38	50	1315	0.000	3170
1008 H	65	53	947.3	652.30	69	898.0	0.000	2570

'N' = Number of observations (non-missing concentrations).

'NALQ' = Number of observations Above Lower limit of Quantification. Summary statistics are not presented if NALQ = 0.

Summary statistics have been calculated by setting concentration values below the lower limit of quantification to zero.

The lower limit of quantification is 250 NG/ML.

PFIZER CONFIDENTIAL Source Data: Table 16.2.5.4.1.1.1 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 16MAY2018 (02:18)

Table 14.4.2.1.1
PF-06410293 Protocol B5381001
Serum Drug Concentration (ng/mL) versus Time Summary (Day 1-43) - PP Analysis Set
Treatment Group=Adalimumab-US

Planned Time Post Dose	N	NALQ	Mean	SD	CV(%)	Median	Min	Max
0 H	67	0						
3 H	67	25	167.3	242.91	145	0.0000	0.000	931
12 H	67	64	1279	789.13	62	1100	0.000	4610
24 H	67	66	1763	975.50	55	1600	0.000	5440
48 H	67	67	2575	1157.1	45	2570	359	6100
72 H	67	67	2905	1183.6	41	2860	545	6080
96 H	67	67	3051	1141.7	37	2940	643	5940
120 H	67	67	3118	1031.2	33	3030	863	5430
144 H	67	67	3124	984.08	32	3100	984	5560
168 H	67	67	3136	973.86	31	3010	1110	5480
192 H	67	67	3146	928.95	30	3040	1130	5140
264 H	65	65	2889	782.21	27	2810	1220	4890
336 H	66	66	2665	670.93	25	2520	1210	4360
504 H	67	67	1830	633.87	35	1820	338	3010
672 H	66	65	1330	595.45	45	1335	0.000	2550
840 H	65	57	935.6	565.39	60	926.0	0.000	2050
1008 H	67	47	625.4	521.26	83	645.0	0.000	1560

'N' = Number of observations (non-missing concentrations).

'NALQ' = Number of observations Above Lower limit of Quantification. Summary statistics are not presented if NALQ = 0.

Summary statistics have been calculated by setting concentration values below the lower limit of quantification to zero.

The lower limit of quantification is 250 NG/ML.

PFIZER CONFIDENTIAL Source Data: Table 16.2.5.4.1.1.1 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 16MAY2018 (02:18)

Table 14.4.2.1.1
PF-06410293 Protocol B5381001
Serum Drug Concentration (ng/mL) versus Time Summary (Day 1-43) - PP Analysis Set
Treatment Group=Adalimumab-EU

Planned Time Post Dose	N	NALQ	Mean	SD	CV(%)	Median	Min	Max
0 H	66	0						
3 H	66	17	143.2	272.30	190	0.0000	0.000	1120
12 H	66	64	1270	846.52	67	1065	0.000	4100
24 H	66	65	1724	963.16	56	1615	0.000	5090
48 H	66	65	2394	1105.4	46	2410	0.000	5020
72 H	66	66	2792	1162.3	42	2775	397	5410
96 H	66	66	2995	1159.5	39	2870	448	5580
120 H	66	66	3059	1084.9	35	3115	517	5420
144 H	66	66	3063	1030.5	34	3000	539	5330
168 H	66	66	3062	973.73	32	3060	626	5320
192 H	66	66	3102	933.33	30	3105	687	5140
264 H	66	66	2872	728.01	25	2930	771	4360
336 H	66	66	2653	586.87	22	2645	885	3920
504 H	66	66	2032	565.10	28	2050	851	3560
672 H	66	66	1531	541.87	35	1575	494	2820
840 H	66	62	1095	551.17	50	1155	0.000	2350
1008 H	65	56	799.0	541.60	68	834.0	0.000	2180

'N' = Number of observations (non-missing concentrations).

'NALQ' = Number of observations Above Lower limit of Quantification. Summary statistics are not presented if NALQ = 0.

Summary statistics have been calculated by setting concentration values below the lower limit of quantification to zero.

The lower limit of quantification is 250 NG/ML.

PFIZER CONFIDENTIAL Source Data: Table 16.2.5.4.1.1.1 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 16MAY2018 (02:18)

Table 14.4.2.1.2
PF-06410293 Protocol B5381001
Serum Drug Concentration (ng/mL) versus Time Summary (Day 71 for Exploratory Analysis) - PP Analysis Set
Treatment Group=Adalimumab-Pfizer

Planned Time Post Dose	N	NALQ	Mean	SD	CV(%)	Median	Min	Max
1680 H	65	25	255.3	370.29	145	0.0000	0.000	1400

'N' = Number of observations (non-missing concentrations).

'NALQ' = Number of observations Above Lower limit of Quantification. Summary statistics are not presented if NALQ = 0.

Summary statistics have been calculated by setting concentration values below the lower limit of quantification to zero.

The lower limit of quantification is 250 NG/ML.

PFIZER CONFIDENTIAL Source Data: Table 16.2.5.4.1.1.2 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 16MAY2018 (02:22)

Table 14.4.2.1.2
PF-06410293 Protocol B5381001
Serum Drug Concentration (ng/mL) versus Time Summary (Day 71 for Exploratory Analysis) - PP Analysis Set
Treatment Group=Adalimumab-US

Planned Time Post Dose	N	NALQ	Mean	SD	CV(%)	Median	Min	Max
1680 H	67	16	108.6	210.73	194	0.0000	0.000	797

'N' = Number of observations (non-missing concentrations).

'NALQ' = Number of observations Above Lower limit of Quantification. Summary statistics are not presented if NALQ = 0.

Summary statistics have been calculated by setting concentration values below the lower limit of quantification to zero.

The lower limit of quantification is 250 NG/ML.

PFIZER CONFIDENTIAL Source Data: Table 16.2.5.4.1.1.2 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 16MAY2018 (02:22)

Table 14.4.2.1.2
PF-06410293 Protocol B5381001
Serum Drug Concentration (ng/mL) versus Time Summary (Day 71 for Exploratory Analysis) - PP Analysis Set
Treatment Group=Adalimumab-EU

Planned Time Post Dose	N	NALQ	Mean	SD	CV(%)	Median	Min	Max
1680 H	65	18	156.9	300.17	191	0.0000	0.000	1140

'N' = Number of observations (non-missing concentrations).

'NALQ' = Number of observations Above Lower limit of Quantification. Summary statistics are not presented if NALQ = 0.


Summary statistics have been calculated by setting concentration values below the lower limit of quantification to zero.

The lower limit of quantification is 250 NG/ML.

PFIZER CONFIDENTIAL Source Data: Table 16.2.5.4.1.1.2 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 16MAY2018 (02:22)

090177e18e74aac2finaIfinal On: 30-May-2018 05:37 (GMT)


Figure 14.4.2.2.1
PF-06410293 Protocol B5381001
Median Serum Drug Concentration - Time Plot (Linear Scale) (Day 1-43) - PP Analysis Set



Summary statistics have been calculated by setting concentration values below the lower limit of quantification to zero.
The lower limit of quantification is 250 NG/ML.
PFIZER CONFIDENTIAL Source Data: Table 14.4.2.1.1 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 16MAY2018 (01:59)

090177e18e74aac3finafina On: 30-May-2018 05:37 (GMT)


Figure 14.4.2.2.2
PF-06410293 Protocol B5381001
Median Serum Drug Concentration - Time Plot (Semilog Scale) (Day 1-43) - PP Analysis Set



Summary statistics have been calculated by setting concentration values below the lower limit of quantification to zero.
The lower limit of quantification is 250 NG/ML.
PFIZER CONFIDENTIAL Source Data: Table 14.4.2.1.1 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 16MAY2018 (02:01)


090177e18e74aac4FinaIOn: 30-May-2018 05:37 (GMT)

Figure 14.4.2.2.3
PF-06410293 Protocol B5381001
Mean Serum Drug Concentration - Time Plot (Linear Scale) (Day 1-43) - PP Analysis Set



Summary statistics have been calculated by setting concentration values below the lower limit of quantification to zero.
The lower limit of quantification is 250 NG/ML.
PFIZER CONFIDENTIAL Source Data: Table 14.4.2.1.1 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 16MAY2018 (02:03)

Figure 14.4.2.2.4
 PF-06410293 Protocol B5381001
 Mean Serum Drug Concentration - Time Plot (Semilog Scale) (Day 1-43) - PP Analysis Set



Summary statistics have been calculated by setting concentration values below the lower limit of quantification to zero.
 The lower limit of quantification is 250 NG/ML.
 PFIZER CONFIDENTIAL Source Data: Table 14.4.2.1.1 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 16MAY2018 (02:05)

Table 14.4.3.1.1.1
PF-06410293 Protocol B5381001
Descriptive Summary of PK Parameters (Day 1-43) - PP Analysis Set
SERUM ADALIMUMAB

		Adalimumab-Pfizer (N=66)	Adalimumab-US (N=67)	Adalimumab-EU (N=66)
Parameter (Units)				
AUC _{0-2wk} (ug.hr/mL)	N*	66	67	66
	Geometric Mean	932.7	880.0	851.9
	Geometric CV (%)	37	35	39
	Arithmetic Mean	988.5	927.5	903.7
	Standard Deviation	318.40	286.06	286.92
	Coefficient of Variation (%)	32	31	32
	Median	985.5	910.0	867.5
	Minimum	301	293	161
AUCT (ug.hr/mL)	Maximum	1960	1630	1530
	N*	66	67	66
	Geometric Mean	2075	1768	1866
	Geometric CV (%)	37	36	33
	Arithmetic Mean	2200	1869	1958
	Standard Deviation	723.80	598.48	579.48
	Coefficient of Variation (%)	33	32	30
	Median	2170	1830	1960
AUC _{inf} (ug.hr/mL)	Minimum	860	717	640
	Maximum	4110	3260	3380
	N*	66	67	66
	Geometric Mean	2700	2177	2388
	Geometric CV (%)	47	43	43
	Arithmetic Mean	2969	2357	2587
	Standard Deviation	1284.7	918.36	1039.7
	Coefficient of Variation (%)	43	39	40
AUC _{inf} (ug.hr/mL)	Median	2770	2250	2490
	Minimum	990	767	718
	Maximum	7240	4430	5670

N: Total number of subjects in the treatment group in the indicated population.

N*: Number of subjects contributing to the summary statistics.

PFIZER CONFIDENTIAL Source Data: Table 16.2.5.5.1.1 Date of SDTM Dataset Creation: 13MAR2018 Date of Table Generation: 15MAY2018 (22:44)

Table 14.4.3.1.1.1
PF-06410293 Protocol B5381001
Descriptive Summary of PK Parameters (Day 1-43) - PP Analysis Set
SERUM ADALIMUMAB

		Adalimumab-Pfizer (N=66)	Adalimumab-US (N=67)	Adalimumab-EU (N=66)
Parameter (Units)				
CL/F (mL/hr)	N*	66	67	66
	Geometric Mean	14.81	18.38	16.75
	Geometric CV (%)	47	43	43
	Arithmetic Mean	16.39	20.04	18.32
	Standard Deviation	7.7692	8.8768	8.7413
	Coefficient of Variation (%)	47	44	48
	Median	14.50	17.70	16.05
	Minimum	5.53	9.04	7.05
	Maximum	40.4	52.2	55.7
Clast (ug/mL)	N*	66	67	66
	Geometric Mean	0.8991	0.6778	0.7548
	Geometric CV (%)	61	55	63
	Arithmetic Mean	1.039	0.7692	0.8800
	Standard Deviation	0.53697	0.38339	0.47591
	Coefficient of Variation (%)	52	50	54
	Median	0.9690	0.7310	0.8715
	Minimum	0.277	0.259	0.259
	Maximum	2.57	1.56	2.18
Cmax (ug/mL)	N*	66	67	66
	Geometric Mean	3.443	3.246	3.200
	Geometric CV (%)	35	34	35
	Arithmetic Mean	3.627	3.414	3.368
	Standard Deviation	1.1339	1.0715	1.0227
	Coefficient of Variation (%)	31	31	30
	Median	3.490	3.270	3.365
	Minimum	1.24	1.22	0.885
	Maximum	7.06	6.10	5.58

N: Total number of subjects in the treatment group in the indicated population.

N*: Number of subjects contributing to the summary statistics.

PFIZER CONFIDENTIAL Source Data: Table 16.2.5.5.1.1 Date of SDTM Dataset Creation: 13MAR2018 Date of Table Generation: 15MAY2018 (22:44)

090177e18e74aa86\Final\Final On: 30-May-2018 05:33 (GMT)

Table 14.4.3.1.1.1
PF-06410293 Protocol B5381001
Descriptive Summary of PK Parameters (Day 1-43) - PP Analysis Set
SERUM ADALIMUMAB

		Adalimumab-Pfizer (N=66)	Adalimumab-US (N=67)	Adalimumab-EU (N=66)
Parameter (Units)				
MRT (hr)	N*	66	67	66
	Geometric Mean	657.0	559.2	626.2
	Geometric CV (%)	39	41	39
	Arithmetic Mean	703.6	605.0	672.1
	Standard Deviation	262.81	249.14	267.38
	Coefficient of Variation (%)	37	41	40
	Median	685.5	558.0	595.0
	Minimum	297	242	333
	Maximum	1410	1360	1540
Tlast (hr)	N*	66	67	66
	Median	1010	1010	1010
	Minimum	672	503	647
	Maximum	1080	1180	1060
Tmax (hr)	N*	66	67	66
	Median	168	168	168
	Minimum	71.8	48.0	48.0
	Maximum	336	335	338
Vz/F (mL)	N*	66	67	66
	Geometric Mean	8127	8561	8655
	Geometric CV (%)	33	35	32
	Arithmetic Mean	8575	9088	9080
	Standard Deviation	3135.9	3532.7	2891.9
	Coefficient of Variation (%)	37	39	32
	Median	7735	8670	8635
	Maximum	21600	26500	17300

N: Total number of subjects in the treatment group in the indicated population.

N*: Number of subjects contributing to the summary statistics.

PFIZER CONFIDENTIAL Source Data: Table 16.2.5.5.1.1 Date of SDTM Dataset Creation: 13MAR2018 Date of Table Generation: 15MAY2018 (22:44)

090177e18e74aa86\Final\Final On: 30-May-2018 05:33 (GMT)

Table 14.4.3.1.1.1
PF-06410293 Protocol B5381001
Descriptive Summary of PK Parameters (Day 1-43) - PP Analysis Set
SERUM ADALIMUMAB

		Adalimumab-Pfizer (N=66)	Adalimumab-US (N=67)	Adalimumab-EU (N=66)
Parameter (Units)				
thalf (hr)	N*	66	67	66
	Arithmetic Mean	427.5	367.3	403.4
	Standard Deviation	200.65	187.64	199.64
	Coefficient of Variation (%)	47	51	49
	Median	422.5	353.0	376.5
	Minimum	140	96.1	141
	Maximum	955	925	1020

N: Total number of subjects in the treatment group in the indicated population.

N*: Number of subjects contributing to the summary statistics.

PFIZER CONFIDENTIAL Source Data: Table 16.2.5.5.1.1 Date of SDTM Dataset Creation: 13MAR2018 Date of Table Generation: 15MAY2018 (22:44)

090177e18e74aa86\Final\Final On: 30-May-2018 05:33 (GMT)

Table 14.4.3.1.1.2
PF-06410293 Protocol B5381001
Descriptive Summary of PK Parameters (Day 1-43) by NAB Status - PP Analysis Set
SERUM ADALIMUMAB
NAB: NEGATIVE

		Adalimumab-Pfizer (N = 31)	Adalimumab-US (N = 24)	Adalimumab-EU (N = 27)
Parameter (Units)				
AUC0-2wk (ug.hr/mL)	N*	31	24	27
	Geometric Mean	1082	920.2	937.6
	Geometric CV (%)	31	40	36
	Arithmetic Mean	1126	978.1	991.9
	Standard Deviation	307.20	316.33	321.78
	Coefficient of Variation (%)	27	32	32
	Median	1100	944.0	1070
	Minimum	413	293	479
	Maximum	1960	1630	1530
AUCT (ug.hr/mL)	N*	31	24	27
	Geometric Mean	2558	2109	2205
	Geometric CV (%)	27	30	26
	Arithmetic Mean	2643	2190	2274
	Standard Deviation	646.59	563.41	564.74
	Coefficient of Variation (%)	24	26	25
	Median	2630	2220	2140
	Minimum	1040	929	1370
	Maximum	4110	3260	3380
AUCinf (ug.hr/mL)	N*	31	24	27
	Geometric Mean	3731	2965	3189
	Geometric CV (%)	31	30	31
	Arithmetic Mean	3892	3078	3332
	Standard Deviation	1122.9	804.74	1039.8
	Coefficient of Variation (%)	29	26	31
	Median	3790	3015	3170
	Minimum	1550	1330	1970
	Maximum	7240	4430	5670

N: Total number of subjects in the treatment group in the indicated population. N*: Number of subjects contributing to the summary statistics.

All not tested subjects have been classified as Nab negative.

PFIZER CONFIDENTIAL Source Data: Table 16.2.5.5.1.1

Date of SDTM Dataset Creation: 13MAR2018

Date of Table Generation: 15MAY2018 (22:46)

Table 14.4.3.1.1.2
PF-06410293 Protocol B5381001
Descriptive Summary of PK Parameters (Day 1-43) by NAB Status - PP Analysis Set
SERUM ADALIMUMAB
NAB: NEGATIVE

		Adalimumab-Pfizer (N = 31)	Adalimumab-US (N = 24)	Adalimumab-EU (N = 27)
Parameter (Units)				
CL/F (mL/hr)	N*	31	24	27
	Geometric Mean	10.72	13.50	12.54
	Geometric CV (%)	31	30	30
	Arithmetic Mean	11.26	14.11	13.07
	Standard Deviation	3.9632	4.8065	3.7298
	Coefficient of Variation (%)	35	34	29
	Median	10.60	13.25	12.60
	Minimum	5.53	9.04	7.05
	Maximum	25.8	30.1	20.3
Clast (ug/mL)	N*	31	24	27
	Geometric Mean	1.366	1.043	1.147
	Geometric CV (%)	35	33	38
	Arithmetic Mean	1.437	1.093	1.223
	Standard Deviation	0.43696	0.31582	0.44187
	Coefficient of Variation (%)	30	29	36
	Median	1.430	1.100	1.170
	Minimum	0.576	0.428	0.470
	Maximum	2.57	1.56	2.18
Cmax (ug/mL)	N*	31	24	27
	Geometric Mean	3.980	3.441	3.537
	Geometric CV (%)	31	38	34
	Arithmetic Mean	4.143	3.649	3.712
	Standard Deviation	1.1209	1.1857	1.1147
	Coefficient of Variation (%)	27	32	30
	Median	4.090	3.490	3.780
	Minimum	1.47	1.22	1.85
	Maximum	7.06	6.08	5.58

N: Total number of subjects in the treatment group in the indicated population. N*: Number of subjects contributing to the summary statistics.

All not tested subjects have been classified as Nab negative.

PFIZER CONFIDENTIAL Source Data: Table 16.2.5.5.1.1

Date of SDTM Dataset Creation: 13MAR2018

Date of Table Generation: 15MAY2018 (22:46)

Table 14.4.3.1.1.2
PF-06410293 Protocol B5381001
Descriptive Summary of PK Parameters (Day 1-43) by NAB Status - PP Analysis Set
SERUM ADALIMUMAB
NAB: NEGATIVE

		Adalimumab-Pfizer (N = 31)	Adalimumab-US (N = 24)	Adalimumab-EU (N = 27)
Parameter (Units)				
MRT (hr)	N*	31	24	27
	Geometric Mean	861.8	802.4	831.4
	Geometric CV (%)	24	28	32
	Arithmetic Mean	886.4	832.0	871.2
	Standard Deviation	220.08	234.90	273.36
	Coefficient of Variation (%)	25	28	31
	Median	882.0	792.0	821.0
	Minimum	548	527	453
	Maximum	1410	1360	1540
Tlast (hr)	N*	31	24	27
	Median	1010	1010	1010
	Minimum	983	983	983
	Maximum	1080	1060	1060
Tmax (hr)	N*	31	24	27
	Median	168	168	168
	Minimum	71.8	72.0	72.0
	Maximum	335	312	338
Vz/F (mL)	N*	31	24	27
	Geometric Mean	8653	10120	9637
	Geometric CV (%)	28	35	31
	Arithmetic Mean	9021	10780	10080
	Standard Deviation	3068.1	4480.6	3113.8
	Coefficient of Variation (%)	34	42	31
	Median	7920	9420	9060
	Minimum	5410	6050	5820
	Maximum	21600	26500	17300

N: Total number of subjects in the treatment group in the indicated population. N*: Number of subjects contributing to the summary statistics.

All not tested subjects have been classified as Nab negative.

PFIZER CONFIDENTIAL Source Data: Table 16.2.5.5.1.1

Date of SDTM Dataset Creation: 13MAR2018

Date of Table Generation: 15MAY2018 (22:46)

Table 14.4.3.1.1.2
PF-06410293 Protocol B5381001
Descriptive Summary of PK Parameters (Day 1-43) by NAB Status - PP Analysis Set
SERUM ADALIMUMAB
NAB: NEGATIVE

		Adalimumab-Pfizer (N = 31)	Adalimumab-US (N = 24)	Adalimumab-EU (N = 27)
Parameter (Units)				
thalf (hr)	N*	31	24	27
	Arithmetic Mean	578.5	543.4	561.3
	Standard Deviation	153.50	169.23	184.45
	Coefficient of Variation (%)	27	31	33
	Median	572.0	501.5	535.0
	Minimum	302	341	230
	Maximum	955	925	1020

N: Total number of subjects in the treatment group in the indicated population. N*: Number of subjects contributing to the summary statistics.

All not tested subjects have been classified as Nab negative.

PFIZER CONFIDENTIAL Source Data: Table 16.2.5.5.1.1

Date of SDTM Dataset Creation: 13MAR2018

Date of Table Generation: 15MAY2018 (22:46)

Table 14.4.3.1.1.2
PF-06410293 Protocol B5381001
Descriptive Summary of PK Parameters (Day 1-43) by NAB Status - PP Analysis Set
SERUM ADALIMUMAB
NAB: POSITIVE

		Adalimumab-Pfizer (N = 35)	Adalimumab-US (N = 43)	Adalimumab-EU (N = 39)
Parameter (Units)				
AUC0-2wk (ug.hr/mL)	N*	35	43	39
	Geometric Mean	817.9	858.3	797.2
	Geometric CV (%)	37	32	39
	Arithmetic Mean	866.5	899.2	842.6
	Standard Deviation	279.16	267.41	246.20
	Coefficient of Variation (%)	32	30	29
	Median	869.0	896.0	834.0
	Minimum	301	388	161
	Maximum	1460	1490	1460
AUCT (ug.hr/mL)	N*	35	43	39
	Geometric Mean	1725	1602	1663
	Geometric CV (%)	33	34	33
	Arithmetic Mean	1808	1689	1739
	Standard Deviation	543.81	544.82	485.99
	Coefficient of Variation (%)	30	32	28
	Median	1780	1680	1820
	Minimum	860	717	640
	Maximum	2930	2850	2890
AUCinf (ug.hr/mL)	N*	35	43	39
	Geometric Mean	2028	1832	1954
	Geometric CV (%)	36	38	38
	Arithmetic Mean	2152	1955	2071
	Standard Deviation	760.12	712.67	664.34
	Coefficient of Variation (%)	35	36	32
	Median	2030	1820	2070
	Minimum	990	767	718
	Maximum	4120	3820	3470

N: Total number of subjects in the treatment group in the indicated population. N*: Number of subjects contributing to the summary statistics.

All not tested subjects have been classified as Nab negative.

PFIZER CONFIDENTIAL Source Data: Table 16.2.5.5.1.1

Date of SDTM Dataset Creation: 13MAR2018

Date of Table Generation: 15MAY2018 (22:46)

Table 14.4.3.1.1.2
PF-06410293 Protocol B5381001
Descriptive Summary of PK Parameters (Day 1-43) by NAB Status - PP Analysis Set
SERUM ADALIMUMAB
NAB: POSITIVE

		Adalimumab-Pfizer (N = 35)	Adalimumab-US (N = 43)	Adalimumab-EU (N = 39)
Parameter (Units)				
CL/F (mL/hr)	N*	35	43	39
	Geometric Mean	19.72	21.83	20.46
	Geometric CV (%)	36	38	38
	Arithmetic Mean	20.93	23.34	21.95
	Standard Deviation	7.5021	8.9423	9.3848
	Coefficient of Variation (%)	36	38	43
	Median	19.70	22.00	19.30
	Minimum	9.72	10.5	11.5
	Maximum	40.4	52.2	55.7
Clast (ug/mL)	N*	35	43	39
	Geometric Mean	0.6206	0.5328	0.5649
	Geometric CV (%)	47	46	55
	Arithmetic Mean	0.6866	0.5885	0.6425
	Standard Deviation	0.33278	0.28816	0.33516
	Coefficient of Variation (%)	48	49	52
	Median	0.6180	0.5000	0.5210
	Minimum	0.277	0.259	0.259
	Maximum	1.56	1.54	1.75
Cmax (ug/mL)	N*	35	43	39
	Geometric Mean	3.028	3.141	2.986
	Geometric CV (%)	32	31	34
	Arithmetic Mean	3.170	3.282	3.130
	Standard Deviation	0.94421	0.99233	0.89246
	Coefficient of Variation (%)	30	30	29
	Median	3.040	3.080	3.160
	Minimum	1.24	1.65	0.885
	Maximum	5.47	6.10	5.24

N: Total number of subjects in the treatment group in the indicated population. N*: Number of subjects contributing to the summary statistics.

All not tested subjects have been classified as Nab negative.

PFIZER CONFIDENTIAL Source Data: Table 16.2.5.5.1.1

Date of SDTM Dataset Creation: 13MAR2018

Date of Table Generation: 15MAY2018 (22:46)

Table 14.4.3.1.1.2
PF-06410293 Protocol B5381001
Descriptive Summary of PK Parameters (Day 1-43) by NAB Status - PP Analysis Set
SERUM ADALIMUMAB
NAB: POSITIVE

		Adalimumab-Pfizer (N = 35)	Adalimumab-US (N = 43)	Adalimumab-EU (N = 39)
Parameter (Units)				
MRT (hr)	N*	35	43	39
	Geometric Mean	516.7	457.2	514.6
	Geometric CV (%)	31	31	28
	Arithmetic Mean	541.7	478.3	534.2
	Standard Deviation	178.47	146.46	153.28
	Coefficient of Variation (%)	33	31	29
	Median	486.0	432.0	501.0
	Minimum	297	242	333
	Maximum	1040	758	932
Tlast (hr)	N*	35	43	39
	Median	1010	961.0	1010
	Minimum	672	503	647
	Maximum	1030	1180	1060
Tmax (hr)	N*	35	43	39
	Median	168	168	168
	Minimum	72.0	48.0	48.0
	Maximum	336	335	336
Vz/F (mL)	N*	35	43	39
	Geometric Mean	7688	7797	8035
	Geometric CV (%)	36	31	30
	Arithmetic Mean	8179	8144	8389
	Standard Deviation	3186.2	2463.4	2544.0
	Coefficient of Variation (%)	39	30	30
	Median	7420	7590	7800
	Minimum	3780	4060	4080
	Maximum	20400	15500	15300

N: Total number of subjects in the treatment group in the indicated population. N*: Number of subjects contributing to the summary statistics.

All not tested subjects have been classified as Nab negative.

PFIZER CONFIDENTIAL Source Data: Table 16.2.5.5.1.1

Date of SDTM Dataset Creation: 13MAR2018

Date of Table Generation: 15MAY2018 (22:46)

Table 14.4.3.1.1.2
PF-06410293 Protocol B5381001
Descriptive Summary of PK Parameters (Day 1-43) by NAB Status - PP Analysis Set
SERUM ADALIMUMAB
NAB: POSITIVE

		Adalimumab-Pfizer (N = 35)	Adalimumab-US (N = 43)	Adalimumab-EU (N = 39)
Parameter (Units)				
thalf (hr)	N*	35	43	39
	Arithmetic Mean	293.7	269.0	294.1
	Standard Deviation	130.25	109.72	122.19
	Coefficient of Variation (%)	44	41	42
	Median	266.0	234.0	242.0
	Minimum	140	96.1	141
	Maximum	689	509	620

N: Total number of subjects in the treatment group in the indicated population. N*: Number of subjects contributing to the summary statistics.

All not tested subjects have been classified as Nab negative.

PFIZER CONFIDENTIAL Source Data: Table 16.2.5.5.1.1 Date of SDTM Dataset Creation: 13MAR2018 Date of Table Generation: 15MAY2018 (22:46)

Table 14.4.3.1.2.1
PF-06410293 Protocol B5381001
Descriptive Summary of PK Parameters (Day 71 for Exploratory Analysis) - PP Analysis Set
SERUM ADALIMUMAB

		Adalimumab-Pfizer (N=25)	Adalimumab-US (N=16)	Adalimumab-EU (N=18)
Parameter (Units)				
AUC0-10wk (ug.hr/mL)	N*	25	16	18
	Geometric Mean	3441	2791	2847
	Geometric CV (%)	20	19	25
	Arithmetic Mean	3508	2839	2927
	Standard Deviation	721.95	537.14	695.40
	Coefficient of Variation (%)	21	19	24
	Median	3430	2800	2870
	Minimum	2500	1960	1760
AUCinf_10wk (ug.hr/mL)	N*	25	16	18
	Geometric Mean	4027	3139	3335
	Geometric CV (%)	23	21	30
	Arithmetic Mean	4130	3201	3472
	Standard Deviation	999.97	663.22	996.22
	Coefficient of Variation (%)	24	21	29
	Median	4050	3190	3205
	Minimum	2760	2200	2000
CLAST_10wk (ug/mL)	N*	25	16	18
	Geometric Mean	0.6120	0.4293	0.4967
	Geometric CV (%)	42	36	56
	Arithmetic Mean	0.6637	0.4549	0.5666
	Standard Deviation	0.28860	0.16534	0.30569
	Coefficient of Variation (%)	43	36	54
	Median	0.6010	0.3975	0.4530
	Minimum	0.319	0.276	0.261
	Maximum	1.40	0.797	1.14

N: Total number of subjects in the treatment group in the indicated population. N*: Number of subjects contributing to the summary statistics.

Concentration values below the lower limit of quantification at Day 71 have been excluded from this present.

The lower limit of quantification is 250 NG/ML.

Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.

PFIZER CONFIDENTIAL Source Data: Table 16.2.5.5.1.2 Date of SDTM Dataset Creation: 13MAR2018 Date of Table Generation: 15MAY2018 (22:48)

Table 14.4.3.1.2.1
PF-06410293 Protocol B5381001
Descriptive Summary of PK Parameters (Day 71 for Exploratory Analysis) - PP Analysis Set
SERUM ADALIMUMAB

		Adalimumab-Pfizer (N=25)	Adalimumab-US (N=16)	Adalimumab-EU (N=18)
Parameter (Units)				
CLF_10wk (mL/hr)	N*	25	16	18
	Geometric Mean	9.929	12.74	11.99
	Geometric CV (%)	23	21	30
	Arithmetic Mean	10.16	12.99	12.49
	Standard Deviation	2.1586	2.6579	3.6888
	Coefficient of Variation (%)	21	20	30
	Median	9.870	12.55	12.50
	Minimum	5.79	8.20	8.01
	Maximum	14.5	18.2	20.0
C _{MAX} _10wk (ug/mL)	N*	25	16	18
	Geometric Mean	4.272	3.757	3.508
	Geometric CV (%)	25	30	35
	Arithmetic Mean	4.394	3.909	3.690
	Standard Deviation	1.0374	1.1239	1.1468
	Coefficient of Variation (%)	24	29	31
	Median	4.450	3.995	3.830
	Minimum	2.35	2.09	1.85
	Maximum	7.06	6.08	5.58
MRT_10wk (hr)	N*	25	16	18
	Geometric Mean	862.5	765.5	855.4
	Geometric CV (%)	27	19	32
	Arithmetic Mean	894.1	779.1	899.3
	Standard Deviation	266.08	156.64	314.94
	Coefficient of Variation (%)	30	20	35
	Median	788.0	762.5	837.0
	Minimum	615	612	597
Maximum	1660	1180	1620	

N: Total number of subjects in the treatment group in the indicated population. N*: Number of subjects contributing to the summary statistics.

Concentration values below the lower limit of quantification at Day 71 have been excluded from this present.

The lower limit of quantification is 250 NG/ML.

Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.

PFIZER CONFIDENTIAL Source Data: Table 16.2.5.5.1.2 Date of SDTM Dataset Creation: 13MAR2018 Date of Table Generation: 15MAY2018 (22:48)

Table 14.4.3.1.2.1
PF-06410293 Protocol B5381001
Descriptive Summary of PK Parameters (Day 71 for Exploratory Analysis) - PP Analysis Set
SERUM ADALIMUMAB

		Adalimumab-Pfizer (N=25)	Adalimumab-US (N=16)	Adalimumab-EU (N=18)
Parameter (Units)				
THALF_10wk (hr)	N*	25	16	18
	Arithmetic Mean	579.3	509.1	561.4
	Standard Deviation	206.20	133.94	242.66
	Coefficient of Variation (%)	36	26	43
	Median	500.0	496.5	497.0
	Minimum	351	349	307
	Maximum	1110	770	1190
TLAST_10wk (hr)	N*	25	16	18
	Median	1680	1680	1680
	Minimum	1510	1560	1510
	Maximum	1800	1680	1680
TMAX_10wk (hr)	N*	25	16	18
	Median	168.0	179.5	190.0
	Minimum	71.8	72.0	72.0
	Maximum	335	312	338
VZF_10wk	N*	25	16	18
	Geometric Mean	7888	9072	9024
	Geometric CV (%)	28	26	34
	Arithmetic Mean	8194	9366	9506
	Standard Deviation	2533.2	2490.3	3148.6
	Coefficient of Variation (%)	31	27	33
	Median	7340	8935	8920
	Minimum	5010	6330	5030
Maximum	15900	14000	15800	

N: Total number of subjects in the treatment group in the indicated population. N*: Number of subjects contributing to the summary statistics.


Concentration values below the lower limit of quantification at Day 71 have been excluded from this present.

The lower limit of quantification is 250 NG/ML.

Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.

PFIZER CONFIDENTIAL Source Data: Table 16.2.5.5.1.2 Date of SDTM Dataset Creation: 13MAR2018 Date of Table Generation: 15MAY2018 (22:48)

Figure 14.4.3.2.1.1
PF-06410293 Protocol B5381001
Box and Whisker Plots for AUCT (ug.hr/mL) by Treatment (Day 1-43) - PP Analysis Set




Geometric mean is calculated for each treatment group.
Star represents the geometric mean and circles represent individual values.
Box plot provides median and 25%/75% quartiles with whiskers to the last data point within 1.5 times the interquartile range.
PFIZER CONFIDENTIAL Source Data: Table 16.2.5.5.1.1 Date of SDTM Dataset Creation: 13MAR2018 Date of Table Generation: 15MAY2018 (23:19)

Figure 14.4.3.2.1.2

PF-06410293 Protocol B5381001

Page 1 of 1

Box and Whisker Plots for AUcT (ug.hr/mL) by Treatment and NAB Status (Day 1-43) - PP Analysis Set



Star represents the mean and circles represent individual values.

Box plot provides median and 25%/75% quartiles with whiskers to the last data point within 1.5 times the interquartile range.


All not tested subjects have been classified as Nab negative.

PFIZER CONFIDENTIAL Source Data: Table 16.2.5.5.1.1

Date of SDTM Dataset Creation: 13MAR2018

Date of Table Generation: 15MAY2018 (23:20)

Figure 14.4.3.2.2.1
PF-06410293 Protocol B5381001
Box and Whisker Plots for AUCinf (ug.hr/mL) by Treatment (Day 1-43) - PP Analysis Set




Geometric mean is calculated for each treatment group.
Star represents the geometric mean and circles represent individual values.
Box plot provides median and 25%/75% quartiles with whiskers to the last data point within 1.5 times the interquartile range.
PFIZER CONFIDENTIAL Source Data: Table 16.2.5.5.1.1 Date of SDTM Dataset Creation: 13MAR2018 Date of Table Generation: 15MAY2018 (23:21)

Figure 14.4.3.2.2.2

PF-06410293 Protocol B5381001

Box and Whisker Plots for AUCinf (ug.hr/mL) by Treatment and NAb Status (Day 1-43) - PP Analysis Set

Page 1 of 1



Star represents the mean and circles represent individual values.

Box plot provides median and 25%/75% quartiles with whiskers to the last data point within 1.5 times the interquartile range.


All not tested subjects have been classified as Nab negative.

PFIZER CONFIDENTIAL Source Data: Table 16.2.5.5.1.1

Date of SDTM Dataset Creation: 13MAR2018

Date of Table Generation: 15MAY2018 (23:22)

Figure 14.4.3.2.3.1
PF-06410293 Protocol B5381001
Box and Whisker Plots for Cmax (ug/mL) by Treatment (Day 1-43) - PP Analysis Set




Geometric mean is calculated for each treatment group.
Star represents the geometric mean and circles represent individual values.
Box plot provides median and 25%/75% quartiles with whiskers to the last data point within 1.5 times the interquartile range.
PFIZER CONFIDENTIAL Source Data: Table 16.2.5.5.1.1 Date of SDTM Dataset Creation: 13MAR2018 Date of Table Generation: 15MAY2018 (23:23)

Figure 14.4.3.2.3.2

PF-06410293 Protocol B5381001

Page 1 of 1

Box and Whisker Plots for Cmax (ug/mL) by Treatment and NAb Status (Day 1-43) - PP Analysis Set



Star represents the mean and circles represent individual values.

Box plot provides median and 25%/75% quartiles with whiskers to the last data point within 1.5 times the interquartile range.


All not tested subjects have been classified as Nab negative.

PFIZER CONFIDENTIAL Source Data: Table 16.2.5.5.1.1

Date of SDTM Dataset Creation: 13MAR2018

Date of Table Generation: 15MAY2018 (23:24)

Figure 14.4.3.2.4.1
PF-06410293 Protocol B5381001
Box and Whisker Plots for AUC0-2wk (ug.hr/mL) by Treatment (Day 1-43) - PP Analysis Set




Geometric mean is calculated for each treatment group.
Star represents the geometric mean and circles represent individual values.
Box plot provides median and 25%/75% quartiles with whiskers to the last data point within 1.5 times the interquartile range.
PFIZER CONFIDENTIAL Source Data: Table 16.2.5.5.1.1 Date of SDTM Dataset Creation: 13MAR2018 Date of Table Generation: 15MAY2018 (23:26)

Figure 14.4.3.2.4.2

PF-06410293 Protocol B5381001

Page 1 of 1

Box and Whisker Plots for AUC0-2wk (ug.hr/mL) by Treatment and NAB Status (Day 1-43) - PP Analysis Set



Star represents the mean and circles represent individual values.

Box plot provides median and 25%/75% quartiles with whiskers to the last data point within 1.5 times the interquartile range.

All not tested subjects have been classified as Nab negative.

PFIZER CONFIDENTIAL Source Data: Table 16.2.5.5.1.1

Date of SDTM Dataset Creation: 13MAR2018

Date of Table Generation: 15MAY2018 (23:27)

Table 14.4.3.3.1.1
PF-06410293 Protocol B5381001
Statistical Summary of Adalimumab PK Parameters (AUC0-2wk, AUCt, AUCinf and Cmax) (Day 1-43) - PP Analysis Set
SERUM ADALIMUMAB

Parameter (Units)	Comparison (Test vs. Reference)	Adjusted Geometric Means		Test vs. Reference	
		Test	Reference	Ratio (%) (Test/Reference)	90% CI (%)
AUC0-2wk (ug.hr/mL)	1. adalimumab-Pfizer vs adalimumab-EU	932.7	851.9	109.48	(98.77, 121.35)
	2. adalimumab-Pfizer vs adalimumab-US	932.7	880.0	105.99	(95.65, 117.44)
	3. adalimumab-EU vs adalimumab-US	851.9	880.0	96.81	(87.37, 107.27)
AUCt (ug.hr/mL)	1. adalimumab-Pfizer vs adalimumab-EU	2075	1866	111.21	(100.77, 122.72)
	2. adalimumab-Pfizer vs adalimumab-US	2075	1768	117.39	(106.41, 129.50)
	3. adalimumab-EU vs adalimumab-US	1866	1768	105.56	(95.69, 116.45)
AUCinf (ug.hr/mL)	1. adalimumab-Pfizer vs adalimumab-EU	2700	2388	113.10	(100.08, 127.82)
	2. adalimumab-Pfizer vs adalimumab-US	2700	2177	124.04	(109.81, 140.11)
	3. adalimumab-EU vs adalimumab-US	2388	2177	109.67	(97.09, 123.88)
Cmax (ug/mL)	1. adalimumab-Pfizer vs adalimumab-EU	3.443	3.200	107.58	(97.73, 118.42)
	2. adalimumab-Pfizer vs adalimumab-US	3.443	3.246	106.07	(96.39, 116.72)
	3. adalimumab-EU vs adalimumab-US	3.200	3.246	98.59	(89.60, 108.49)

Statistical Analysis was performed on the log-transformed parameters. Values presented in the table have been back-transformed from the log scale to the original scale.

PFIZER CONFIDENTIAL Source Data: Table 16.1.9.2.1.1 Date of SDTM Dataset Creation: 13MAR2018 Date of Table Generation: 15MAY2018 (22:50)

Table 14.4.3.3.2.1

PF-06410293 Protocol B5381001

Statistical Summary of Adalimumab PK Parameters (AUC0-2wk, AUCt, AUCinf and Cmax) (Weight as Covariate for Exploratory Analysis) (Day 1-43)

- PP Analysis Set

SERUM ADALIMUMAB

Parameter (Units)	Comparison (Test vs. Reference)	Adjusted Geometric Means		Test vs. Reference	
		Test	Reference	Ratio (%) (Test/Reference)	90% CI (%)
AUC0-2wk (ug.hr/mL)	1. adalimumab-Pfizer vs adalimumab-EU	922.7	872.4	105.76	(97.08, 115.22)
	2. adalimumab-Pfizer vs adalimumab-US	922.7	868.8	106.21	(97.54, 115.64)
	3. adalimumab-EU vs adalimumab-US	872.4	868.8	100.42	(92.20, 109.37)
AUCt (ug.hr/mL)	1. adalimumab-Pfizer vs adalimumab-EU	2055	1908	107.71	(99.11, 117.05)
	2. adalimumab-Pfizer vs adalimumab-US	2055	1747	117.62	(108.28, 127.75)
	3. adalimumab-EU vs adalimumab-US	1908	1747	109.20	(100.51, 118.64)
AUCinf (ug.hr/mL)	1. adalimumab-Pfizer vs adalimumab-EU	2673	2442	109.47	(98.07, 122.21)
	2. adalimumab-Pfizer vs adalimumab-US	2673	2151	124.28	(111.41, 138.64)
	3. adalimumab-EU vs adalimumab-US	2442	2151	113.53	(101.74, 126.69)
Cmax (ug/mL)	1. adalimumab-Pfizer vs adalimumab-EU	3.406	3.276	103.98	(96.21, 112.39)
	2. adalimumab-Pfizer vs adalimumab-US	3.406	3.205	106.28	(98.38, 114.82)
	3. adalimumab-EU vs adalimumab-US	3.276	3.205	102.21	(94.59, 110.45)

Statistical Analysis was performed on the log-transformed parameters. Values presented in the table have been back-transformed from the log scale to the original scale.

PFIZER CONFIDENTIAL Source Data: Table 16.1.9.2.2.1

Date of SDTM Dataset Creation: 13MAR2018

Date of Table Generation: 15MAY2018 (22:52)

Table 14.4.5.1.1.1
PF-06410293 Protocol B5381001
Summary of Immunogenicity Data (ADA) Incidence by Treatment Group - Full Analysis Set

Visit	Criteria	Adalimumab-Pfizer (N=69)		Adalimumab-US (N=71)		Adalimumab-EU (N=70)	
		n	(%)	n	(%)	n	(%)
Day 1	Negative < 1.88	66	(95.7%)	69	(97.2%)	68	(97.1%)
	Positive >= 1.88	3	(4.3%)	2	(2.8%)	2	(2.9%)
	No Sample	0		0		0	
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)
Day 15	Negative < 1.88	55	(79.7%)	48	(67.6%)	53	(75.7%)
	Positive >= 1.88	14	(20.3%)	22	(31.0%)	15	(21.4%)
	No Sample	0		1	(1.4%)	2	(2.9%)
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)
Day 29	Negative < 1.88	44	(63.8%)	43	(60.6%)	51	(72.9%)
	Positive >= 1.88	23	(33.3%)	27	(38.0%)	19	(27.1%)
	No Sample	2	(2.9%)	1	(1.4%)	0	
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)
Day 43	Negative < 1.88	37	(53.6%)	35	(49.3%)	38	(54.3%)
	Positive >= 1.88	30	(43.5%)	36	(50.7%)	32	(45.7%)
	No Sample	2	(2.9%)	0		0	
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)
Day 71	Negative < 1.88	9	(13.0%)	4	(5.6%)	9	(12.9%)
	Positive >= 1.88	59	(85.5%)	67	(94.4%)	60	(85.7%)
	No Sample	1	(1.4%)	0		1	(1.4%)
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)

090177e18e74aa8b\Final\Final On: 30-May-2018 05:33 (GMT)

Table 14.4.5.1.1.1
PF-06410293 Protocol B5381001
Summary of Immunogenicity Data (ADA) Incidence by Treatment Group - Full Analysis Set

Visit	Criteria	Adalimumab-Pfizer (N=69)		Adalimumab-US (N=71)		Adalimumab-EU (N=70)	
		n	(%)	n	(%)	n	(%)
Follow-Up	Negative < 1.88	0		0		0	
	Positive >= 1.88	0		0		1	(1.4%)
	No Sample	69	(100.0%)	71	(100.0%)	69	(98.6%)
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)
Overall	Negative < 1.88	10	(14.5%)	4	(5.6%)	7	(10.0%)
	Positive >= 1.88	59	(85.5%)	67	(94.4%)	63	(90.0%)
	No Sample	0		0		0	
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)

090177e18e74aa8b\Final\Final On: 30-May-2018 05:33 (GMT)

Table 14.4.5.1.2.1.1
PF-06410293 Protocol B5381001
Summary of Immunogenicity Data (ADA) Incidence for Cross-reactivity by Treatment Group - Full Analysis Set

Visit	Criteria	Adalimumab-Pfizer (N=69)		Adalimumab-US (N=71)		Adalimumab-EU (N=70)	
		n	(%)	n	(%)	n	(%)
Day 1	Negative < 1.88	1	(1.4%)	1	(1.4%)	0	
	Positive >= 1.88	2	(2.9%)	1	(1.4%)	2	(2.9%)
	Not Tested	66	(95.7%)	69	(97.2%)	68	(97.1%)
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)
Day 15	Negative < 1.88	3	(4.3%)	1	(1.4%)	3	(4.3%)
	Positive >= 1.88	11	(15.9%)	21	(29.6%)	12	(17.1%)
	Not Tested	55	(79.7%)	49	(69.0%)	55	(78.6%)
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)
Day 29	Negative < 1.88	7	(10.1%)	3	(4.2%)	4	(5.7%)
	Positive >= 1.88	16	(23.2%)	24	(33.8%)	15	(21.4%)
	Not Tested	46	(66.7%)	44	(62.0%)	51	(72.9%)
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)
Day 43	Negative < 1.88	6	(8.7%)	2	(2.8%)	4	(5.7%)
	Positive >= 1.88	24	(34.8%)	34	(47.9%)	28	(40.0%)
	Not Tested	39	(56.5%)	35	(49.3%)	38	(54.3%)
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)
Day 71	Negative < 1.88	2	(2.9%)	2	(2.8%)	0	
	Positive >= 1.88	57	(82.6%)	65	(91.5%)	60	(85.7%)
	Not Tested	10	(14.5%)	4	(5.6%)	10	(14.3%)
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)

090177e18e74aa8c\Final\Final On: 30-May-2018 05:33 (GMT)

Table 14.4.5.1.2.1.1
PF-06410293 Protocol B5381001
Summary of Immunogenicity Data (ADA) Incidence for Cross-reactivity by Treatment Group - Full Analysis Set

Visit	Criteria	Adalimumab-Pfizer (N=69)		Adalimumab-US (N=71)		Adalimumab-EU (N=70)	
		n	(%)	n	(%)	n	(%)
Follow-Up	Negative < 1.88	0		0		0	
	Positive >= 1.88	0		0		1	(1.4%)
	Not Tested	69	(100.0%)	71	(100.0%)	69	(98.6%)
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)
Overall	Negative < 1.88	2	(2.9%)	2	(2.8%)	0	
	Positive >= 1.88	57	(82.6%)	65	(91.5%)	63	(90.0%)
	Not Tested	10	(14.5%)	4	(5.6%)	7	(10.0%)
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)

090177e18e74aa8c\Final\Final On: 30-May-2018 05:33 (GMT)

Table 14.4.5.1.2.2.1
PF-06410293 Protocol B5381001
Summary of Immunogenicity Data (ADA) Incidence for Cross-reactivity for Positive ADA - Full Analysis Set

Visit	Adalimumab-Pfizer			Adalimumab-US			Adalimumab-EU		
	Cross-reactivity Positive	ADA Positive	%	Cross-reactivity Positive	ADA Positive	%	Cross-reactivity Positive	ADA Positive	%
Day 1	2	3	67%	1	2	50%	2	2	100%
Day 15	11	14	79%	21	22	95%	12	15	80%
Day 29	16	23	70%	24	27	89%	15	19	79%
Day 43	24	30	80%	34	36	94%	28	32	88%
Day 71	57	59	97%	65	67	97%	60	60	100%
Follow-Up	0	0	0	0	0	0	1	1	100%
Overall	57	59	97%	65	67	97%	63	63	100%
Total Samples	110	129	85%	145	154	94%	118	129	91%

Percentage is calculated as number of cross-reactivity positive samples/number of ADA positive samples * 100%

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.5.1 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 28MAY2018 (22:22)

Table 14.4.5.1.3.1
PF-06410293 Protocol B5381001
Summary of Immunogenicity Data (ADA) Titer - Full Analysis Set

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)
Visit				
Day 1	n	3	2	2
	25% Quartile	1.95	1.88	1.88
	75% Quartile	2.25	2.68	2.21
	Median	2.10	2.28	2.05
	Min	1.95	1.88	1.88
	Max	2.25	2.68	2.21
Day 15	n	14	22	15
	25% Quartile	2.31	2.27	1.88
	75% Quartile	2.35	2.51	2.35
	Median	2.33	2.32	2.28
	Min	1.88	1.88	1.88
	Max	2.70	4.18	2.66
Day 29	n	23	27	19
	25% Quartile	2.17	1.88	1.88
	75% Quartile	2.34	2.34	2.31
	Median	2.30	2.11	2.17
	Min	1.88	1.88	1.88
	Max	2.71	3.89	2.78
Day 43	n	30	36	32
	25% Quartile	2.11	2.18	2.01
	75% Quartile	2.67	2.87	2.46
	Median	2.35	2.42	2.26
	Min	1.88	1.88	1.88
	Max	3.12	3.81	3.10

N means total number of subjects in the treatment group in the indicated population.

n means total number of subjects with positive ADA(titer \geq 1.88).

Overall row is based on the maximum per positive ADA subject.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.5.1 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 16MAY2018 (03:18)

Table 14.4.5.1.3.1
PF-06410293 Protocol B5381001
Summary of Immunogenicity Data (ADA) Titer - Full Analysis Set

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)
Visit				
Day 71	n	59	67	60
	25% Quartile	2.35	2.65	2.46
	75% Quartile	3.44	3.53	3.47
	Median	3.05	3.05	2.83
	Min	1.88	1.88	1.88
	Max	4.18	4.69	4.23
Follow-Up	n			1
	25% Quartile			3.34
	75% Quartile			3.34
	Median			3.34
	Min			3.34
	Max			3.34
Overall	n	59	67	63
	25% Quartile	2.35	2.65	2.43
	75% Quartile	3.44	3.53	3.46
	Median	3.05	3.08	2.82
	Min	1.88	1.88	1.88
	Max	4.18	4.69	4.23

N means total number of subjects in the treatment group in the indicated population.

n means total number of subjects with positive ADA(titer \geq 1.88).

Overall row is based on the maximum per positive ADA subject.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.5.1 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 16MAY2018 (03:18)

Table 14.4.5.1.4.1
PF-06410293 Protocol B5381001
Summary of Immunogenicity Data (ADA) Onset Day - Full Analysis Set

Visit	Adalimumab-Pfizer (N=69)		Adalimumab-US (N=71)		Adalimumab-EU (N=70)	
	n	(%)	n	(%)	n	(%)
Day 1	3	(4.3%)	2	(2.8%)	2	(2.9%)
Day 15	11	(15.9%)	20	(28.2%)	13	(18.6%)
Day 29	12	(17.4%)	13	(18.3%)	7	(10.0%)
Day 43	10	(14.5%)	10	(14.1%)	17	(24.3%)
Day 71	23	(33.3%)	22	(31.0%)	24	(34.3%)

Number (%) for subjects with first positive ADA test for each time point.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.5.1 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 16MAY2018 (03:22)

Table 14.4.5.2.1.1
PF-06410293 Protocol B5381001
Summary of Neutralizing Antibody (NAB) Incidence by Treatment Group - Full Analysis Set

Visit	Criteria	Adalimumab-Pfizer (N=69)		Adalimumab-US (N=71)		Adalimumab-EU (N=70)	
		n	(%)	n	(%)	n	(%)
Day 1	Negative < 0.70	1	(1.4%)	1	(1.4%)	1	(1.4%)
	Positive >= 0.70	2	(2.9%)	1	(1.4%)	1	(1.4%)
	Not Tested	66	(95.7%)	69	(97.2%)	68	(97.1%)
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)
Day 15	Negative < 0.70	14	(20.3%)	21	(29.6%)	15	(21.4%)
	Positive >= 0.70	0		1	(1.4%)	0	
	Not Tested	55	(79.7%)	49	(69.0%)	55	(78.6%)
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)
Day 29	Negative < 0.70	20	(29.0%)	23	(32.4%)	17	(24.3%)
	Positive >= 0.70	3	(4.3%)	4	(5.6%)	2	(2.9%)
	Not Tested	46	(66.7%)	44	(62.0%)	51	(72.9%)
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)
Day 43	Negative < 0.70	16	(23.2%)	16	(22.5%)	21	(30.0%)
	Positive >= 0.70	14	(20.3%)	20	(28.2%)	11	(15.7%)
	Not Tested	39	(56.5%)	35	(49.3%)	38	(54.3%)
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)
Day 71	Negative < 0.70	22	(31.9%)	20	(28.2%)	19	(27.1%)
	Positive >= 0.70	37	(53.6%)	47	(66.2%)	41	(58.6%)
	Not Tested	10	(14.5%)	4	(5.6%)	10	(14.3%)
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)

Subject ██████ in treatment Adalimumab-US and ██████ in treatment Adalimumab-EU with positive value at pre-dose only, are counted as negative in overall.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.5.2 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 16MAY2018 (03:10)

Table 14.4.5.2.1.1
PF-06410293 Protocol B5381001
Summary of Neutralizing Antibody (NAB) Incidence by Treatment Group - Full Analysis Set

Visit	Criteria	Adalimumab-Pfizer (N=69)		Adalimumab-US (N=71)		Adalimumab-EU (N=70)	
		n	(%)	n	(%)	n	(%)
Follow-Up	Negative < 0.70	0		0		0	
	Positive >= 0.70	0		0		1	(1.4%)
	Not Tested	69	(100.0%)	71	(100.0%)	69	(98.6%)
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)
Overall	Negative < 0.70	22	(31.9%)	20	(28.2%)	20	(28.6%)
	Positive >= 0.70	37	(53.6%)	47	(66.2%)	43	(61.4%)
	Not Tested	10	(14.5%)	4	(5.6%)	7	(10.0%)
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)

Subject [REDACTED] in treatment Adalimumab-US and [REDACTED] in treatment Adalimumab-EU with positive value at pre-dose only, are counted as negative in overall.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.5.2 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 16MAY2018 (03:10)

Table 14.4.5.2.2.1.1
PF-06410293 Protocol B5381001
Summary of Neutralizing Antibody (NAB) Incidence for Cross-reactivity by Treatment Group - Full Analysis Set

Visit	Criteria	Adalimumab-Pfizer (N=69)		Adalimumab-US (N=71)		Adalimumab-EU (N=70)	
		n	(%)	n	(%)	n	(%)
Day 1	Negative < 0.70	0		0		0	
	Positive >= 0.70	1	(1.4%)	0		1	(1.4%)
	Not Tested	68	(98.6%)	71	(100.0%)	69	(98.6%)
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)
Day 15	Negative < 0.70	0		0		0	
	Positive >= 0.70	0		1	(1.4%)	0	
	Not Tested	69	(100.0%)	70	(98.6%)	70	(100.0%)
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)
Day 29	Negative < 0.70	0		0		0	
	Positive >= 0.70	2	(2.9%)	4	(5.6%)	2	(2.9%)
	Not Tested	67	(97.1%)	67	(94.4%)	68	(97.1%)
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)
Day 43	Negative < 0.70	0		1	(1.4%)	0	
	Positive >= 0.70	14	(20.3%)	19	(26.8%)	11	(15.7%)
	Not Tested	55	(79.7%)	51	(71.8%)	59	(84.3%)
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)
Day 71	Negative < 0.70	0		2	(2.8%)	0	
	Positive >= 0.70	37	(53.6%)	45	(63.4%)	41	(58.6%)
	Not Tested	32	(46.4%)	24	(33.8%)	29	(41.4%)
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)

Subject ██████ in treatment Adalimumab-EU with positive value at pre-dose only, is counted as negative in overall.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.5.2 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 16MAY2018 (03:12)

Table 14.4.5.2.2.1.1
PF-06410293 Protocol B5381001
Summary of Neutralizing Antibody (NAB) Incidence for Cross-reactivity by Treatment Group - Full Analysis Set

Visit	Criteria	Adalimumab-Pfizer (N=69)		Adalimumab-US (N=71)		Adalimumab-EU (N=70)	
		n	(%)	n	(%)	n	(%)
Follow-Up	Negative < 0.70	0		0		0	
	Positive >= 0.70	0		0		1	(1.4%)
	Not Tested	69	(100.0%)	71	(100.0%)	69	(98.6%)
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)
Overall	Negative < 0.70	0		2	(2.8%)	1	(1.4%)
	Positive >= 0.70	37	(53.6%)	45	(63.4%)	43	(61.4%)
	Not Tested	32	(46.4%)	24	(33.8%)	26	(37.1%)
	Total	69	(100.0%)	71	(100.0%)	70	(100.0%)

Subject [REDACTED] in treatment Adalimumab-EU with positive value at pre-dose only, is counted as negative in overall.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.5.2 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 16MAY2018 (03:12)

Table 14.4.5.2.2.1
PF-06410293 Protocol B5381001
Summary of Neutralizing Antibody (NAB) Incidence for Cross-reactivity for Positive NAB - Full Analysis Set

Visit	Adalimumab-Pfizer			Adalimumab-US			Adalimumab-EU		
	Cross-reactivity Positive	NAB Positive	%	Cross-reactivity Positive	NAB Positive	%	Cross-reactivity Positive	NAB Positive	%
Day 1	1	2	50%	0	1	0	1	1	100%
Day 15	0	0	0	1	1	100%	0	0	0
Day 29	2	3	67%	4	4	100%	2	2	100%
Day 43	14	14	100%	19	20	95%	11	11	100%
Day 71	37	37	100%	45	47	96%	41	41	100%
Follow-Up	0	0	0	0	0	0	1	1	100%
Overall	37	37	100%	45	47	96%	43	43	100%
Total Samples	54	56	96%	69	73	95%	56	56	100%

Percentage is calculated as number of cross-reactivity positive samples/number of NAB positive samples * 100%

Subject ██████ in treatment Adalimumab-EU with cross-reactivity positive value at pre-dose only, is counted as negative in overall.

Subject ██████ in treatment Adalimumab-US and ██████ in treatment Adalimumab-EU with positive value at pre-dose only, are counted as negative in overall

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.5.2 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 28MAY2018 (22:21)

Table 14.4.5.2.3.1
PF-06410293 Protocol B5381001
Summary of Neutralizing Antibody (NAB) Quartiles by Treatment Group - Full Analysis Set

	Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)
Nab Titer Quartile*			
Number of subjects tested Nab positive	37 (53.6%)	47 (66.2%)	43 (61.4%)
Number of subjects in each Nab titer quartile			
Lower 25% (≤ 1.19)	8	13	11
25% to 50% (1.19 - 1.46)	11	7	14
50% - 75% (1.46 - 1.84)	9	10	13
Upper 75% (> 1.84)	9	17	5

*The Nab titer quartile was based upon the range of maximum post-dose Nab titers of all Nab-positive subjects.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.5.2 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 16MAY2018 (03:24)

Table 14.4.5.2.4.1
PF-06410293 Protocol B5381001
Summary of Neutralizing Antibody (NAB) Titer - Full Analysis Set

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)
Visit				
Day 1	n	2	1	1
	25% Quartile	0.90	1.62	0.86
	75% Quartile	0.91	1.62	0.86
	Median	0.91	1.62	0.86
	Min	0.90	1.62	0.86
	Max	0.91	1.62	0.86
Day 15	n		1	
	25% Quartile		1.90	
	75% Quartile		1.90	
	Median		1.90	
	Min		1.90	
	Max		1.90	
Day 29	n	3	4	2
	25% Quartile	0.75	1.33	1.25
	75% Quartile	1.24	1.94	1.75
	Median	0.91	1.66	1.50
	Min	0.75	1.15	1.25
	Max	1.24	2.07	1.75
Day 43	n	14	20	11
	25% Quartile	1.13	1.05	0.99
	75% Quartile	1.76	1.74	1.60
	Median	1.25	1.27	1.24
	Min	0.89	0.90	0.95
	Max	2.12	2.50	1.70

N means total number of subjects in the treatment group in the indicated population.

n means total number of subjects with positive NAB(titer \geq 0.70).

Overall row is based on the maximum per positive NAB subject.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.5.2 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 16MAY2018 (03:20)

Table 14.4.5.2.4.1
PF-06410293 Protocol B5381001
Summary of Neutralizing Antibody (NAB) Titer - Full Analysis Set

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)
Visit				
Day 71	n	37	47	41
	25% Quartile	1.22	1.17	1.18
	75% Quartile	1.77	1.91	1.55
	Median	1.46	1.51	1.32
	Min	0.87	0.82	0.90
	Max	2.15	2.52	2.18
Follow-Up	n			1
	25% Quartile			1.35
	75% Quartile			1.35
	Median			1.35
	Min			1.35
	Max			1.35
Overall	n	37	47	43
	25% Quartile	1.22	1.17	1.19
	75% Quartile	1.77	1.95	1.62
	Median	1.46	1.53	1.35
	Min	0.87	0.82	0.90
	Max	2.15	2.52	2.18

N means total number of subjects in the treatment group in the indicated population.

n means total number of subjects with positive NAB(titer \geq 0.70).

Overall row is based on the maximum per positive NAB subject.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.5.2 Date of SDTM Dataset Creation: 24APR2018 Date of Table Generation: 16MAY2018 (03:20)

15. REFERENCES

1. Adalimumab Biologics License Application #125057/0, Clinical Pharmacology and Biopharmaceutics Review, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research, FDA, 31 December 2002 (accessed 7 March 2013). <http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm092770.pdf>.
2. FDA. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. 2003; Available from: <http://www.fda.gov/downloads/Drugs/.../Guidances/ucm070124.pdf>.
3. EMA. Guideline on the Investigation of Bioequivalence. 2010; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf.
4. EMA. Guideline on Similar Biological Medicinal Products. 2005; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf.